<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03903822</url>
  </required_header>
  <id_info>
    <org_study_id>B7931022</org_study_id>
    <secondary_id>2018-003050-24</secondary_id>
    <nct_id>NCT03903822</nct_id>
  </id_info>
  <brief_title>Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis</brief_title>
  <official_title>A PHASE 2B, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP, DOSE RANGING STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06700841 CREAM APPLIED ONCE OR TWICE DAILY FOR 6 WEEKS IN PARTICIPANTS WITH MILD OR MODERATE ATOPIC DERMATITIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to provide data on efficacy, safety, tolerability and PK of&#xD;
      multiple topical formulation concentrations of PF-06700841 topical cream in the treatment of&#xD;
      mild to moderate atopic dermatitis (AD). The study is intended to enable selection of the&#xD;
      dose and dosing regimen (once daily [QD] vs twice daily [BID] application) for the future&#xD;
      clinical development of topical PF-06700841.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 13, 2019</start_date>
  <completion_date type="Actual">May 7, 2020</completion_date>
  <primary_completion_date type="Actual">May 7, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions(head and neck, upper limbs, trunk [including axillae and groin] and lower limbs [including buttocks]) on4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each 4 body region: 0 (0%), 1 (&gt;0 to &lt;10%), 2 (10 to &lt;30%), 3 (30 to &lt;50%), 4 (50 to &lt;70%), 5 (70 to &lt;90%) and 6 (90 to 100%). Total EASI score =0.1*Ah*(Eh+Ih+Exh+Lh) + 0.2*Au*(Eu+Iu+ExU+Lu) + 0.3*At*(Et+It+Ext+Lt) + 0.4*Al*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Investigator's Global Assessment (IGA) Score Clear (0) or Almost Clear (1) and a Reduction From Baseline of Greater Than or Equal to ( &gt;=2) Points at Week 6: Non-responder Imputation</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>IGA assesses severity of participant's AD on a 5 point scale. 0= clear, no inflammatory signs of AD; 1= almost clear, AD not fully cleared- light pink residual lesions (except post-inflammatory hyperpigmentation), just perceptible erythema, papulation/induration lichenification, excoriation, and no oozing/crusting; 2= mild AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting; 3= moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting and 4= severe AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting. Higher scores indicating more severity of AD. Assessment excluded soles, palms and scalp.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions(head and neck, upper limbs, trunk [including axillae and groin] and lower limbs [including buttocks]) on4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each 4 body region: 0 (0%), 1 (&gt;0 to &lt;10%), 2 (10 to &lt;30%), 3 (30 to &lt;50%), 4 (50 to &lt;70%), 5 (70 to &lt;90%) and 6 (90 to 100%). Total EASI score =0.1*Ah*(Eh+Ih+Exh+Lh) + 0.2*Au*(Eu+Iu+ExU+Lu) + 0.3*At*(Et+It+Ext+Lt) + 0.4*Al*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving &gt;=2 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation</measure>
    <time_frame>Baseline, Weeks 1, 2, 3, 4 and 6</time_frame>
    <description>The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants at specified time points were asked the following question: &quot;How would you rate your itch due to AD at the worst moment during the previous 24 hours?&quot; The scale ranged from 0-10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving &gt;=4 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4, 6 and Follow-up Visit: Non-responder Imputation</measure>
    <time_frame>Baseline, Weeks 1, 2, 3, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)</time_frame>
    <description>The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants at specified time points were asked the following question: &quot;How would you rate your itch due to AD at the worst moment during the previous 24 hours?&quot; The scale ranged from 0-10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Affected Body Surface Area (BSA) at Weeks 1, 2, 3, 4, 6 and Follow-up Visit</measure>
    <time_frame>Baseline, Weeks 1, 2, 3, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)</time_frame>
    <description>4 body regions were evaluated: head and neck, upper limbs, trunk (including axillae and groin) and lower limbs (including buttocks). Scalp, palms and soles were excluded. BSA was calculated using handprint method. Number of handprints (size of participant's full palmer hand) fitting in the affected area of a body region was estimated. Maximum number of handprints were 10 for head and neck, 20 for upper limbs, 30 for trunk and 40 for lower limbs. Surface area of body region equivalent to 1 handprint: 1 handprint was equal to 10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% for lower limbs. Percent BSA for a body region was calculated as = total number of handprints in a body region * % surface area equivalent to 1 handprint. Overall % BSA for an individual: arithmetic mean of % BSA of all 4 body regions, ranged from 0 to 100%, with higher values representing greater severity of AD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving &gt;=75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation</measure>
    <time_frame>Baseline, Weeks 1, 2, 3, 4 and 6</time_frame>
    <description>EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions(head and neck, upper limbs, trunk [including axillae and groin] and lower limbs [including buttocks]) on4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each 4 body region: 0 (0%), 1 (&gt;0 to &lt;10%), 2 (10 to &lt;30%), 3 (30 to &lt;50%), 4 (50 to &lt;70%), 5 (70 to &lt;90%) and 6 (90 to 100%). Total EASI score =0.1*Ah*(Eh+Ih+Exh+Lh) + 0.2*Au*(Eu+Iu+ExU+Lu) + 0.3*At*(Et+It+Ext+Lt) + 0.4*Al*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline (Day 1) up to at least 28 days after last dose of study drug (approximately up to Week 11)</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. Treatment-emergent were events between first dose of investigational product and up to 28 days after the last dose of investigational product that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and all non-SAEs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Pre-defined Criteria For Vital Signs</measure>
    <time_frame>Baseline up to Week 6</time_frame>
    <description>Pre-defined criteria included: 1) Diastolic blood pressure (DBP), a) sitting DBP: change of &gt;= 20 millimeter of mercury (mmHg) increase, b) sitting DBP: change of &gt;=20mmHg decrease, c) supine DBP: less than (&lt;) 50 mmHg, d) supine DBP: change of &gt;= 20mmHg increase, e) supine DBP: change of &gt;= 20mmHg decrease; 2) Systolic blood pressure (SBP), a) sitting SBP: &lt;90 mmHg, b) sitting SBP: change of &gt;=30mmHg increase, c) sitting SBP: change of &gt;=30mmHg decrease, d) supine SBP: change of &gt;=30mmHg increase, e) supine SBP: change of &gt;=30mmHg decrease and f) Supine SBP: value &lt;90mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Laboratory Abnormalities</measure>
    <time_frame>Baseline (Day 1) up to at least 28 days after last dose of study drug (approximately up to Week 11)</time_frame>
    <description>Hemoglobin (HGB),hematocrit,erythrocytes (ery.),HDL cholesterol (chl.)&lt;0.8*lower limit of normal(LLN);reticulocytes (ret.), ret./ery. (%)&lt;0.5*LLN,&gt;1.5*upper limit of normal (ULN);ery. mean corpuscular (EMC) volume,EMC HGB,EMC HGB concentration,potassium,chloride,calcium,bicarbonate&lt;0.9*LLN,&gt;1.1*ULN;platelets&lt;0.5*LLN,&gt;1.75*ULN;leukocytes (leu.),glucose&lt;0.6*LLN,&gt;1.5*ULN;lymphocytes (lym.), lym./leu.(%), neutrophils (neu.), neu./leu. (%), protein,albumin &lt;0.8*LLN,&gt;1.2*ULN;basophils (bas.), bas./leu.(%), eosinophils (eos.), eos./leu., monocytes (mon.), mon./leu.(%), urate &gt;1.2*ULN;bilirubin (total, direct, indirect)&gt;1.5*ULN;aspartate/alanine aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase&gt;3.0*ULN;urea nitrogen, creatinine, triglycerides, chl.&gt;1.3*ULN; sodium &lt;0.95*LLN,&gt;1.05*ULN; creatine kinase &gt;2.0*ULN;Urine: pH&lt;4.5,&gt;8;glucose, ketones, protein, HGB, urobilinogen,bilirubin,nitrite,leukocyte esterase&gt;=1;ery., leu.&gt;= 20;hyaline casts&gt;1;bacteria&gt;20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Findings</measure>
    <time_frame>Baseline up to Week 6</time_frame>
    <description>Clinically significant ECG criteria included PR interval: value greater than (&gt;) 280 millisecond (msec), percentage change greater than equal to (&gt;=) 25/50 percentage, QRS interval: value &gt;120 msec, percentage change &gt;= 50% and QT interval corrected using the Fridericia's formula (QTCF) value 450 msec and 30&lt;=change&lt;60.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Chemistry-Lactate Dehydrogenase Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit</measure>
    <time_frame>Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Chemistry- Protein and Albumin Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit</measure>
    <time_frame>Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Chemistry- Urea Nitrogen, Urate, Calcium and Glucose Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit</measure>
    <time_frame>Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Clinical Chemistry- Sodium, Potassium, Chloride and Bicarbonate Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit</measure>
    <time_frame>Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology- Hemoglobin Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit</measure>
    <time_frame>Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology - Hematocrit, Reticulocytes/Erythrocytes, Lymphocytes/Leukocytes, Neutrophils/Leukocytes, Basophils/Leukocytes, Eosinophils/Leukocytes and Monocytes/Leukocytes Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit</measure>
    <time_frame>Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology- Erythrocytes and Reticulocytes Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit</measure>
    <time_frame>Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hematology- Platelets, Leukocytes, Lymphocytes, Neutrophils, Basophils, Eosinophils and Monocytes Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit</measure>
    <time_frame>Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Lipids Profile Values at Week 6</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Lipid parameters that were assessed: high density lipoprotein (HDL) cholesterol, triglycerides, cholesterol, low density lipoprotein (LDL) cholesterol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Ratio of LDL Cholesterol to HDL Cholesterol Lipids Profile at Week 6</measure>
    <time_frame>Baseline, Week 6</time_frame>
    <description>Mean change in total cholesterol/HDL cholesterol ratio was assessed and reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Electrocardiogram (ECG) Parameter- Heart Rate at Weeks 2 and 6</measure>
    <time_frame>Baseline, Weeks 2 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PR, QRS, QTCF and QT Interval at Weeks 2 and 6</measure>
    <time_frame>Baseline, Weeks 2 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vital Signs- Blood Pressure (BP) at Weeks 2 and 6</measure>
    <time_frame>Baseline, Weeks 2 and 6</time_frame>
    <description>Blood pressure included supine and sitting systolic and diastolic BP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vital Signs- Pulse Rate at Weeks 2 and 6</measure>
    <time_frame>Baseline, Weeks 2 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vital Signs- Temperature at Weeks 2 and 6</measure>
    <time_frame>Baseline, Weeks 2 and 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Each Severity Grade in Local Tolerability Assessments</measure>
    <time_frame>Day 1 and any day on of Week 1, 2, 4, 6: pre dose (before application of IP) and post dose (after application of IP); Follow up visit (28 days after last dose of study drug = maximum up to Day 71) and Early termination (anytime within week 11)</time_frame>
    <description>Local tolerability skin assessments were performed by the investigator and graded based on severity from grade 0 to 4 as: grade 0=none (no evidence of local intolerance); grade 1=mild (minimal erythema and/or oedema, slight glazed appearance); grade 2= moderate (definite erythema and/or oedema with peeling and/or cracking but needs no adaptation of posology) grade 3=severe (erythema, oedema glazing with fissures, few vesicles or papules consider removing topical agent [if still in place]) and grade 4= very severe (strong reaction spreading beyond the treated area, bullous reaction, erosions: removal of topical agent [if still in place]). Higher grades indicated worsening of condition. Only those categories in which at least 1 participant had data were reported.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">292</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>PF-06700841 0.1% cream QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06700841 0.1% cream applied once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06700841 0.3% cream QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06700841 0.3% cream applied once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06700841 1% cream QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06700841 1% cream applied once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06700841 3% cream QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06700841 3% cream applied once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06700841 0.3% cream BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06700841 0.3% cream applied twice daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06700841 1% cream BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06700841 1% cream applied twice daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle cream QD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle cream applied once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle cream BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle cream applied twice daily (BID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06700841</intervention_name>
    <description>PF-06700841 topical cream</description>
    <arm_group_label>PF-06700841 0.1% cream QD</arm_group_label>
    <arm_group_label>PF-06700841 0.3% cream BID</arm_group_label>
    <arm_group_label>PF-06700841 0.3% cream QD</arm_group_label>
    <arm_group_label>PF-06700841 1% cream BID</arm_group_label>
    <arm_group_label>PF-06700841 1% cream QD</arm_group_label>
    <arm_group_label>PF-06700841 3% cream QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle (Placebo)</intervention_name>
    <description>Vehicle topical cream</description>
    <arm_group_label>Vehicle cream BID</arm_group_label>
    <arm_group_label>Vehicle cream QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of Atopic Dermatitis for at least 3 months&#xD;
&#xD;
          -  Investigator's Global Assessment (IGA) Score of 2 or 3&#xD;
&#xD;
          -  Eczema Area Severity Index (EASI) score of 3-21&#xD;
&#xD;
          -  Body Surface Area (BSA) of 2-20%&#xD;
&#xD;
          -  Peak pruritus-Numerical Rating Scale (PPNRS) of Grade 2 or more&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other forms of dermatological diseases (other than atopic dermatitis)&#xD;
&#xD;
          -  Fitzpatrick skin type score greater than 5&#xD;
&#xD;
          -  Clinically significant abnormal ECG, vital signs, and laboratory values&#xD;
&#xD;
          -  Infection with HBV, HCV, herpes zoster or tuberculosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Center of Alabama, LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Dermatology and Plastic Surgery/CCT</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Dermatology and Plastic Surgery</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Dermatology &amp; Clinical Research Institute</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First OC Dermatology</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beach Allergy and Asthma Specialty Group, A Medical Corporation</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Science Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Associates, LLC</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <zip>06606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Physicians of Connecticut</name>
      <address>
        <city>Shelton</city>
        <state>Connecticut</state>
        <zip>06484</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yolanda C. Holmes, MD</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olympian Clinical Research</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accel Research Sites - DeLand Clinical Research Unit</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Imaging</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Solutions Through Advanced Research, Inc</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leavitt Medical Associates of Florida d/b/a Ameriderm Research</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research PC</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sneeze, Wheeze &amp; Itch Associates, LLC</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DS Research</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DS Research</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MediSearch Clinical Trials</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Consulting Services, PLLC</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vital Prospects Clinical Research Institute, PC</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Concepts</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanenbaum Dermatology Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>studies in Dermatology, LLC</name>
      <address>
        <city>Cypress</city>
        <state>Texas</state>
        <zip>77433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies, LTD.LLP</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventavia Research Group LLC</name>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <zip>76054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies, LTD. LLP</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Clinical Research, LLC</name>
      <address>
        <city>Franklin</city>
        <state>Virginia</state>
        <zip>23851</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Dermatology and Skin Cancer Center</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Australian Clinical Research Network</name>
      <address>
        <city>Maroubra</city>
        <state>New South Wales</state>
        <zip>2035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emeritus Research</name>
      <address>
        <city>Camberwell</city>
        <state>Victoria</state>
        <zip>3124</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinclair Dermatology</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabrini Hospital</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Skin and Venereal Diseases EOOD - Sofia</name>
      <address>
        <city>Sofia</city>
        <zip>1404</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCC Alexandrovska</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Consultative Center - Fokus-5 - Medical Establishment for Outpatient Care OOD</name>
      <address>
        <city>Sofia</city>
        <zip>1463</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wiseman Dermatology Research Inc.</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3M 3Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SKiN Health</name>
      <address>
        <city>Cobourg</city>
        <state>Ontario</state>
        <zip>K9A 4J9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovaderm Research Inc.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 2V1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diex Recherche Sherbrooke Inc.</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1L 0H8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emovis GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10629</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rothhaar Studien GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10783</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ISA - Interdisciplinary Study Association GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bielefeld gem.GmbH</name>
      <address>
        <city>Bielefeld</city>
        <zip>33647</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn AöR</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MENSINGDERMA research GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>22391</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ Alstermed GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>22391</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatologische Gemeinschaftspraxis</name>
      <address>
        <city>Mahlow</city>
        <zip>15831</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Schwerin GmbH</name>
      <address>
        <city>Schwerin</city>
        <zip>19055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem Altalanos Orvostudomanyi Kar</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bacs-Kiskun Megyei Korhaz Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar Oktato Korhaza</name>
      <address>
        <city>Kecskemet</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRU Hungary Kft.</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kitago Dermatology Clinic</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>003-0833</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakatsuhifuka Clinic</name>
      <address>
        <city>Kita-ku, Osaka-shi</city>
        <state>Osaka</state>
        <zip>531-0072</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkside Hiroo Ladies Clinic</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>106-0047</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanpopo Skin Clinic</name>
      <address>
        <city>Ota Ku</city>
        <state>Tokyo</state>
        <zip>143-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinjuku Minamiguchi Dermatology Skin Clinic</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Jitai-kai Tachikawa Dermatology Clinic</name>
      <address>
        <city>Tachikawa</city>
        <state>Tokyo</state>
        <zip>190-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aesthetic dermatology clinic of Prof. J. Kisis</name>
      <address>
        <city>Riga</city>
        <zip>LV-1003</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health and Aesthetics Ltd</name>
      <address>
        <city>Riga</city>
        <zip>LV-1009</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Outpatient Clinic of Ventspils</name>
      <address>
        <city>Ventspils</city>
        <zip>LV3601</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Specjalistyczny Ośrodek Dermatologiczny DERMAL s.c.</name>
      <address>
        <city>Bialystok</city>
        <zip>15-453</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NASZ LEKARZ Przychodnie Medyczne</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MTZ Clinical Research Sp. z o.o</name>
      <address>
        <city>Warszawa</city>
        <zip>02-106</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WroMedica I. Bielicka, A. Strzalkowska s.c.</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-685</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Japan</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B7931022</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 20, 2019</study_first_submitted>
  <study_first_submitted_qc>April 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2019</study_first_posted>
  <results_first_submitted>January 20, 2021</results_first_submitted>
  <results_first_submitted_qc>March 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 29, 2021</results_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild-to-Moderate Atopic Dermatitis</keyword>
  <keyword>topical</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>PF-06700841</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 31, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT03903822/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 20, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT03903822/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vehicle Cream Once Daily (QD)</title>
          <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible atopic dermatitis (AD) areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
        </group>
        <group group_id="P2">
          <title>PF-06700841 0.1% Cream QD</title>
          <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 percent (%) cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
        </group>
        <group group_id="P3">
          <title>PF-06700841 0.3% Cream QD</title>
          <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
        </group>
        <group group_id="P4">
          <title>PF-06700841 1.0% Cream QD</title>
          <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
        </group>
        <group group_id="P5">
          <title>PF-06700841 3.0% Cream QD</title>
          <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
        </group>
        <group group_id="P6">
          <title>Vehicle Cream Twice Daily (BID)</title>
          <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
        </group>
        <group group_id="P7">
          <title>PF-06700841 0.3% Cream BID</title>
          <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
        </group>
        <group group_id="P8">
          <title>PF-06700841 1.0% Cream BID</title>
          <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Phase (6 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="37"/>
                <participants group_id="P5" count="36"/>
                <participants group_id="P6" count="36"/>
                <participants group_id="P7" count="36"/>
                <participants group_id="P8" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="32"/>
                <participants group_id="P5" count="31"/>
                <participants group_id="P6" count="25"/>
                <participants group_id="P7" count="31"/>
                <participants group_id="P8" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused Further Treatment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow up Phase (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37">Participants not completing treatment phase could also start this phase.</participants>
                <participants group_id="P2" count="37">Participants not completing treatment phase could also start this phase.</participants>
                <participants group_id="P3" count="36">Participants not completing treatment phase could also start this phase.</participants>
                <participants group_id="P4" count="37">Participants not completing treatment phase could also start this phase.</participants>
                <participants group_id="P5" count="36">Participants not completing treatment phase could also start this phase.</participants>
                <participants group_id="P6" count="36">Participants not completing treatment phase could also start this phase.</participants>
                <participants group_id="P7" count="36">Participants not completing treatment phase could also start this phase.</participants>
                <participants group_id="P8" count="37">Participants not completing treatment phase could also start this phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="33"/>
                <participants group_id="P5" count="32"/>
                <participants group_id="P6" count="28"/>
                <participants group_id="P7" count="31"/>
                <participants group_id="P8" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="8"/>
                <participants group_id="P7" count="5"/>
                <participants group_id="P8" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused Further Study Procedures</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Vehicle Cream Once Daily (QD)</title>
          <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
        </group>
        <group group_id="B2">
          <title>PF-06700841 0.1% Cream QD</title>
          <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
        </group>
        <group group_id="B3">
          <title>PF-06700841 0.3% Cream QD</title>
          <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
        </group>
        <group group_id="B4">
          <title>PF-06700841 1.0% Cream QD</title>
          <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
        </group>
        <group group_id="B5">
          <title>PF-06700841 3.0% Cream QD</title>
          <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
        </group>
        <group group_id="B6">
          <title>Vehicle Cream Twice Daily (BID)</title>
          <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
        </group>
        <group group_id="B7">
          <title>PF-06700841 0.3% Cream BID</title>
          <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
        </group>
        <group group_id="B8">
          <title>PF-06700841 1.0% Cream BID</title>
          <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="36"/>
            <count group_id="B4" value="37"/>
            <count group_id="B5" value="36"/>
            <count group_id="B6" value="36"/>
            <count group_id="B7" value="36"/>
            <count group_id="B8" value="37"/>
            <count group_id="B9" value="292"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.1" spread="16.80"/>
                    <measurement group_id="B2" value="40.8" spread="15.35"/>
                    <measurement group_id="B3" value="43.4" spread="16.43"/>
                    <measurement group_id="B4" value="38.4" spread="12.90"/>
                    <measurement group_id="B5" value="40.5" spread="12.30"/>
                    <measurement group_id="B6" value="42.3" spread="18.18"/>
                    <measurement group_id="B7" value="39.4" spread="17.27"/>
                    <measurement group_id="B8" value="38.1" spread="15.34"/>
                    <measurement group_id="B9" value="40.2" spread="15.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="16"/>
                    <measurement group_id="B8" value="20"/>
                    <measurement group_id="B9" value="156"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="20"/>
                    <measurement group_id="B8" value="17"/>
                    <measurement group_id="B9" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="35"/>
                    <measurement group_id="B6" value="33"/>
                    <measurement group_id="B7" value="35"/>
                    <measurement group_id="B8" value="33"/>
                    <measurement group_id="B9" value="277"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="20"/>
                    <measurement group_id="B7" value="22"/>
                    <measurement group_id="B8" value="24"/>
                    <measurement group_id="B9" value="174"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation</title>
        <description>EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions(head and neck, upper limbs, trunk [including axillae and groin] and lower limbs [including buttocks]) on4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each 4 body region: 0 (0%), 1 (&gt;0 to &lt;10%), 2 (10 to &lt;30%), 3 (30 to &lt;50%), 4 (50 to &lt;70%), 5 (70 to &lt;90%) and 6 (90 to 100%). Total EASI score =0.1*Ah*(Eh+Ih+Exh+Lh) + 0.2*Au*(Eu+Iu+ExU+Lu) + 0.3*At*(Et+It+Ext+Lt) + 0.4*Al*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Full analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Missing data were imputed with multiple imputation method assuming responses are similar to the corresponding vehicle arm under the MAR assumption</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream Once Daily (QD)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 0.1% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 0.3% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 1.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 3.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Cream Twice Daily (BID)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 0.3% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841 1.0% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation</title>
          <description>EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions(head and neck, upper limbs, trunk [including axillae and groin] and lower limbs [including buttocks]) on4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each 4 body region: 0 (0%), 1 (&gt;0 to &lt;10%), 2 (10 to &lt;30%), 3 (30 to &lt;50%), 4 (50 to &lt;70%), 5 (70 to &lt;90%) and 6 (90 to 100%). Total EASI score =0.1*Ah*(Eh+Ih+Exh+Lh) + 0.2*Au*(Eu+Iu+ExU+Lu) + 0.3*At*(Et+It+Ext+Lt) + 0.4*Al*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.</description>
          <population>Full analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Missing data were imputed with multiple imputation method assuming responses are similar to the corresponding vehicle arm under the MAR assumption</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="36"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.4" lower_limit="-57.3" upper_limit="-31.6"/>
                    <measurement group_id="O2" value="-58.3" lower_limit="-71.2" upper_limit="-45.5"/>
                    <measurement group_id="O3" value="-64.6" lower_limit="-77.1" upper_limit="-52.1"/>
                    <measurement group_id="O4" value="-70.1" lower_limit="-82.1" upper_limit="-58.0"/>
                    <measurement group_id="O5" value="-67.9" lower_limit="-80.6" upper_limit="-55.3"/>
                    <measurement group_id="O6" value="-47.6" lower_limit="-57.5" upper_limit="-37.7"/>
                    <measurement group_id="O7" value="-58.6" lower_limit="-67.5" upper_limit="-49.7"/>
                    <measurement group_id="O8" value="-75.0" lower_limit="-83.8" upper_limit="-66.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of covariance (ANCOVA) contained fixed factors of treatment and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1040</p_value>
            <method>ANCOVA</method>
            <param_type>Least square (LS) mean difference</param_type>
            <param_value>-13.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.04</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-32.1</ci_lower_limit>
            <ci_upper_limit>4.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ANCOVA contained fixed factors of treatment and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0334</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-20.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.00</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.3</ci_lower_limit>
            <ci_upper_limit>-2.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ANCOVA contained fixed factors of treatment and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0086</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-25.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.75</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.3</ci_lower_limit>
            <ci_upper_limit>-8.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>ANCOVA contained fixed factors of treatment and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0158</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-23.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.93</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.5</ci_lower_limit>
            <ci_upper_limit>-5.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>ANCOVA contained fixed factors of treatment and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0879</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-11.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.11</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.3</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>ANCOVA contained fixed factors of treatment and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-27.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.11</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.7</ci_lower_limit>
            <ci_upper_limit>-14.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Investigator's Global Assessment (IGA) Score Clear (0) or Almost Clear (1) and a Reduction From Baseline of Greater Than or Equal to ( &gt;=2) Points at Week 6: Non-responder Imputation</title>
        <description>IGA assesses severity of participant's AD on a 5 point scale. 0= clear, no inflammatory signs of AD; 1= almost clear, AD not fully cleared- light pink residual lesions (except post-inflammatory hyperpigmentation), just perceptible erythema, papulation/induration lichenification, excoriation, and no oozing/crusting; 2= mild AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting; 3= moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting and 4= severe AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting. Higher scores indicating more severity of AD. Assessment excluded soles, palms and scalp.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Full analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Non-Responder Imputation (NRI) method: participants with missing values were considered to be non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream Once Daily (QD)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 0.1% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 0.3% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 1.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 3.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Cream Twice Daily (BID)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 0.3% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841 1.0% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Investigator's Global Assessment (IGA) Score Clear (0) or Almost Clear (1) and a Reduction From Baseline of Greater Than or Equal to ( &gt;=2) Points at Week 6: Non-responder Imputation</title>
          <description>IGA assesses severity of participant's AD on a 5 point scale. 0= clear, no inflammatory signs of AD; 1= almost clear, AD not fully cleared- light pink residual lesions (except post-inflammatory hyperpigmentation), just perceptible erythema, papulation/induration lichenification, excoriation, and no oozing/crusting; 2= mild AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting; 3= moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting and 4= severe AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting. Higher scores indicating more severity of AD. Assessment excluded soles, palms and scalp.</description>
          <population>Full analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Non-Responder Imputation (NRI) method: participants with missing values were considered to be non-responders.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="36"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" lower_limit="4.8" upper_limit="22.2"/>
                    <measurement group_id="O2" value="29.7" lower_limit="18.5" upper_limit="43.3"/>
                    <measurement group_id="O3" value="33.3" lower_limit="21.3" upper_limit="47.0"/>
                    <measurement group_id="O4" value="40.5" lower_limit="28.0" upper_limit="54.4"/>
                    <measurement group_id="O5" value="44.4" lower_limit="30.2" upper_limit="59.1"/>
                    <measurement group_id="O6" value="13.9" lower_limit="6.9" upper_limit="25.4"/>
                    <measurement group_id="O7" value="33.3" lower_limit="21.3" upper_limit="47.0"/>
                    <measurement group_id="O8" value="27.0" lower_limit="15.5" upper_limit="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0244</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>18.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.4</ci_lower_limit>
            <ci_upper_limit>34.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0113</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>22.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.8</ci_lower_limit>
            <ci_upper_limit>38.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0018</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>29.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.0</ci_lower_limit>
            <ci_upper_limit>45.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>33.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.7</ci_lower_limit>
            <ci_upper_limit>49.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0289</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>19.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.8</ci_lower_limit>
            <ci_upper_limit>36.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1145</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>13.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>29.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation</title>
        <description>EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions(head and neck, upper limbs, trunk [including axillae and groin] and lower limbs [including buttocks]) on4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each 4 body region: 0 (0%), 1 (&gt;0 to &lt;10%), 2 (10 to &lt;30%), 3 (30 to &lt;50%), 4 (50 to &lt;70%), 5 (70 to &lt;90%) and 6 (90 to 100%). Total EASI score =0.1*Ah*(Eh+Ih+Exh+Lh) + 0.2*Au*(Eu+Iu+ExU+Lu) + 0.3*At*(Et+It+Ext+Lt) + 0.4*Al*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Full analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Missing data were imputed with multiple imputation method assuming responses are similar to the corresponding vehicle arm under the MAR assumption</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream Once Daily (QD)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 0.1% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 0.3% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 1.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 3.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Cream Twice Daily (BID)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 0.3% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841 1.0% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 6: Multiple Imputation</title>
          <description>EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions(head and neck, upper limbs, trunk [including axillae and groin] and lower limbs [including buttocks]) on4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each 4 body region: 0 (0%), 1 (&gt;0 to &lt;10%), 2 (10 to &lt;30%), 3 (30 to &lt;50%), 4 (50 to &lt;70%), 5 (70 to &lt;90%) and 6 (90 to 100%). Total EASI score =0.1*Ah*(Eh+Ih+Exh+Lh) + 0.2*Au*(Eu+Iu+ExU+Lu) + 0.3*At*(Et+It+Ext+Lt) + 0.4*Al*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.</description>
          <population>Full analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Missing data were imputed with multiple imputation method assuming responses are similar to the corresponding vehicle arm under the MAR assumption</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="36"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" lower_limit="-4.1" upper_limit="-2.3"/>
                    <measurement group_id="O2" value="-4.5" lower_limit="-5.4" upper_limit="-3.6"/>
                    <measurement group_id="O3" value="-4.6" lower_limit="-5.5" upper_limit="-3.7"/>
                    <measurement group_id="O4" value="-4.8" lower_limit="-5.7" upper_limit="-3.9"/>
                    <measurement group_id="O5" value="-5.5" lower_limit="-6.4" upper_limit="-4.7"/>
                    <measurement group_id="O6" value="-3.6" lower_limit="-4.3" upper_limit="-3.0"/>
                    <measurement group_id="O7" value="-4.4" lower_limit="-5.0" upper_limit="-3.8"/>
                    <measurement group_id="O8" value="-5.3" lower_limit="-5.9" upper_limit="-4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ANCOVA contained fixed factors of treatment and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0488</p_value>
            <method>ANCOVA</method>
            <param_type>LS mean difference</param_type>
            <param_value>-1.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.790</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.61</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ANCOVA contained fixed factors of treatment and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0413</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.37</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.788</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.66</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ANCOVA contained fixed factors of treatment and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0200</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.59</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.773</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.86</ci_lower_limit>
            <ci_upper_limit>-0.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>ANCOVA contained fixed factors of treatment and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.758</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.58</ci_lower_limit>
            <ci_upper_limit>-1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>ANCOVA contained fixed factors of treatment and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0727</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.78</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.535</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.66</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>ANCOVA contained fixed factors of treatment and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0010</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.534</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.52</ci_lower_limit>
            <ci_upper_limit>-0.77</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving &gt;=2 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation</title>
        <description>The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants at specified time points were asked the following question: &quot;How would you rate your itch due to AD at the worst moment during the previous 24 hours?&quot; The scale ranged from 0-10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.</description>
        <time_frame>Baseline, Weeks 1, 2, 3, 4 and 6</time_frame>
        <population>Full analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure. NRI method: participants with missing values were considered to be non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream Once Daily (QD)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 0.1% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 0.3% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 1.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 3.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Cream Twice Daily (BID)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 0.3% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841 1.0% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving &gt;=2 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation</title>
          <description>The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants at specified time points were asked the following question: &quot;How would you rate your itch due to AD at the worst moment during the previous 24 hours?&quot; The scale ranged from 0-10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.</description>
          <population>Full analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure. NRI method: participants with missing values were considered to be non-responders.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="36"/>
                <count group_id="O7" value="35"/>
                <count group_id="O8" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" lower_limit="7.3" upper_limit="29.3"/>
                    <measurement group_id="O2" value="16.7" lower_limit="7.5" upper_limit="30.2"/>
                    <measurement group_id="O3" value="20.0" lower_limit="11.0" upper_limit="33.8"/>
                    <measurement group_id="O4" value="29.7" lower_limit="18.5" upper_limit="43.3"/>
                    <measurement group_id="O5" value="44.4" lower_limit="30.2" upper_limit="59.1"/>
                    <measurement group_id="O6" value="13.9" lower_limit="6.9" upper_limit="25.4"/>
                    <measurement group_id="O7" value="28.6" lower_limit="16.4" upper_limit="41.9"/>
                    <measurement group_id="O8" value="25.7" lower_limit="15.4" upper_limit="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3" lower_limit="14.5" upper_limit="37.0"/>
                    <measurement group_id="O2" value="30.6" lower_limit="18.9" upper_limit="44.0"/>
                    <measurement group_id="O3" value="42.9" lower_limit="30.0" upper_limit="58.1"/>
                    <measurement group_id="O4" value="48.6" lower_limit="34.3" upper_limit="63.0"/>
                    <measurement group_id="O5" value="61.1" lower_limit="47.0" upper_limit="74.6"/>
                    <measurement group_id="O6" value="25.0" lower_limit="14.9" upper_limit="38.0"/>
                    <measurement group_id="O7" value="45.7" lower_limit="31.7" upper_limit="60.8"/>
                    <measurement group_id="O8" value="37.1" lower_limit="23.6" upper_limit="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" lower_limit="11.2" upper_limit="34.3"/>
                    <measurement group_id="O2" value="38.9" lower_limit="25.4" upper_limit="53.0"/>
                    <measurement group_id="O3" value="48.6" lower_limit="33.8" upper_limit="63.5"/>
                    <measurement group_id="O4" value="59.5" lower_limit="45.6" upper_limit="72.0"/>
                    <measurement group_id="O5" value="58.3" lower_limit="44.0" upper_limit="71.0"/>
                    <measurement group_id="O6" value="33.3" lower_limit="21.3" upper_limit="47.0"/>
                    <measurement group_id="O7" value="51.4" lower_limit="36.5" upper_limit="66.2"/>
                    <measurement group_id="O8" value="57.1" lower_limit="41.9" upper_limit="70.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1" lower_limit="22.2" upper_limit="49.3"/>
                    <measurement group_id="O2" value="38.9" lower_limit="25.4" upper_limit="53.0"/>
                    <measurement group_id="O3" value="51.4" lower_limit="36.5" upper_limit="66.2"/>
                    <measurement group_id="O4" value="62.2" lower_limit="48.0" upper_limit="75.2"/>
                    <measurement group_id="O5" value="58.3" lower_limit="44.0" upper_limit="71.0"/>
                    <measurement group_id="O6" value="30.6" lower_limit="18.9" upper_limit="44.0"/>
                    <measurement group_id="O7" value="60.0" lower_limit="44.8" upper_limit="74.0"/>
                    <measurement group_id="O8" value="60.0" lower_limit="44.8" upper_limit="74.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5" lower_limit="28.0" upper_limit="54.4"/>
                    <measurement group_id="O2" value="41.7" lower_limit="29.0" upper_limit="56.0"/>
                    <measurement group_id="O3" value="51.4" lower_limit="36.5" upper_limit="66.2"/>
                    <measurement group_id="O4" value="56.8" lower_limit="43.2" upper_limit="70.7"/>
                    <measurement group_id="O5" value="61.1" lower_limit="47.0" upper_limit="74.6"/>
                    <measurement group_id="O6" value="30.6" lower_limit="18.9" upper_limit="44.0"/>
                    <measurement group_id="O7" value="60.0" lower_limit="44.8" upper_limit="74.0"/>
                    <measurement group_id="O8" value="60.0" lower_limit="44.8" upper_limit="74.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 1: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5246</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.7</ci_lower_limit>
            <ci_upper_limit>16.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 1: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3906</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>3.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.5</ci_lower_limit>
            <ci_upper_limit>19.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 1: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1193</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>13.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>30.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At Week 1: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0048</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>28.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.8</ci_lower_limit>
            <ci_upper_limit>45.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>At Week 1: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0777</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>14.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>31.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At Week 1: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1245</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>11.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.3</ci_lower_limit>
            <ci_upper_limit>28.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 2: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3322</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>6.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.2</ci_lower_limit>
            <ci_upper_limit>24.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 2: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0535</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>18.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>36.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 2: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0159</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>24.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.5</ci_lower_limit>
            <ci_upper_limit>41.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At Week 2: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>36.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.4</ci_lower_limit>
            <ci_upper_limit>54.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>At Week 2: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0386</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>20.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.5</ci_lower_limit>
            <ci_upper_limit>38.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At Week 2: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1485</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>12.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.4</ci_lower_limit>
            <ci_upper_limit>30.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 3: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0620</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>17.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>34.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 3: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0089</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>26.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.5</ci_lower_limit>
            <ci_upper_limit>44.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 3: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>37.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>17.5</ci_lower_limit>
            <ci_upper_limit>54.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At Week 3: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>36.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.4</ci_lower_limit>
            <ci_upper_limit>54.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>At Week 3: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0711</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>18.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>37.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At Week 3: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0266</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>23.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.7</ci_lower_limit>
            <ci_upper_limit>42.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At week 4: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4173</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>3.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.3</ci_lower_limit>
            <ci_upper_limit>23.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 4: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1096</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>16.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.3</ci_lower_limit>
            <ci_upper_limit>35.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 4: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0133</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>27.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.1</ci_lower_limit>
            <ci_upper_limit>45.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At Week 4: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0304</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>23.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.6</ci_lower_limit>
            <ci_upper_limit>41.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>At Week 4: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0078</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>29.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.2</ci_lower_limit>
            <ci_upper_limit>47.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At Week 4: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0078</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>29.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.2</ci_lower_limit>
            <ci_upper_limit>47.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 6: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4966</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.4</ci_lower_limit>
            <ci_upper_limit>20.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 6: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2753</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>10.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.3</ci_lower_limit>
            <ci_upper_limit>30.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 6: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1036</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>16.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.2</ci_lower_limit>
            <ci_upper_limit>35.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At Week 6: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0457</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>20.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>39.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>At Week 6: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0078</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>29.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.2</ci_lower_limit>
            <ci_upper_limit>47.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At Week 6: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0078</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>29.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.2</ci_lower_limit>
            <ci_upper_limit>47.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving &gt;=4 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4, 6 and Follow-up Visit: Non-responder Imputation</title>
        <description>The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants at specified time points were asked the following question: &quot;How would you rate your itch due to AD at the worst moment during the previous 24 hours?&quot; The scale ranged from 0-10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.</description>
        <time_frame>Baseline, Weeks 1, 2, 3, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)</time_frame>
        <population>Full analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure. NRI method: participants with missing values were considered to be non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream Once Daily (QD)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 0.1% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 0.3% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 1.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 3.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Cream Twice Daily (BID)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 0.3% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841 1.0% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving &gt;=4 Points Reduction in Peak Pruritus Numerical Rating Scale (PP-NRS) From Baseline at Weeks 1, 2, 3, 4, 6 and Follow-up Visit: Non-responder Imputation</title>
          <description>The severity of itch (pruritus) due to AD was assessed using a horizontal NRS. Participants at specified time points were asked the following question: &quot;How would you rate your itch due to AD at the worst moment during the previous 24 hours?&quot; The scale ranged from 0-10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.</description>
          <population>Full analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure. NRI method: participants with missing values were considered to be non-responders.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="8.2"/>
                    <measurement group_id="O2" value="3.3" lower_limit="0.4" upper_limit="14.0"/>
                    <measurement group_id="O3" value="3.1" lower_limit="0.3" upper_limit="13.1"/>
                    <measurement group_id="O4" value="16.1" lower_limit="8.1" upper_limit="29.7"/>
                    <measurement group_id="O5" value="10.7" lower_limit="4.0" upper_limit="23.8"/>
                    <measurement group_id="O6" value="3.3" lower_limit="0.4" upper_limit="14.0"/>
                    <measurement group_id="O7" value="3.3" lower_limit="0.4" upper_limit="14.0"/>
                    <measurement group_id="O8" value="11.1" lower_limit="4.2" upper_limit="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="3.4" upper_limit="20.2"/>
                    <measurement group_id="O2" value="10.0" lower_limit="3.7" upper_limit="22.1"/>
                    <measurement group_id="O3" value="9.4" lower_limit="3.5" upper_limit="20.7"/>
                    <measurement group_id="O4" value="19.4" lower_limit="8.8" upper_limit="32.7"/>
                    <measurement group_id="O5" value="25.0" lower_limit="13.9" upper_limit="40.0"/>
                    <measurement group_id="O6" value="10.0" lower_limit="3.7" upper_limit="22.1"/>
                    <measurement group_id="O7" value="13.3" lower_limit="5.9" upper_limit="27.9"/>
                    <measurement group_id="O8" value="33.3" lower_limit="20.4" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" lower_limit="5.4" upper_limit="25.1"/>
                    <measurement group_id="O2" value="23.3" lower_limit="12.9" upper_limit="37.6"/>
                    <measurement group_id="O3" value="15.6" lower_limit="7.8" upper_limit="28.7"/>
                    <measurement group_id="O4" value="32.3" lower_limit="18.7" upper_limit="48.2"/>
                    <measurement group_id="O5" value="32.1" lower_limit="19.7" upper_limit="47.3"/>
                    <measurement group_id="O6" value="10.0" lower_limit="3.7" upper_limit="22.1"/>
                    <measurement group_id="O7" value="20.0" lower_limit="9.1" upper_limit="33.9"/>
                    <measurement group_id="O8" value="37.0" lower_limit="22.1" upper_limit="54.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" lower_limit="8.2" upper_limit="31.3"/>
                    <measurement group_id="O2" value="26.7" lower_limit="14.0" upper_limit="41.6"/>
                    <measurement group_id="O3" value="28.1" lower_limit="17.0" upper_limit="43.3"/>
                    <measurement group_id="O4" value="35.5" lower_limit="21.3" upper_limit="51.8"/>
                    <measurement group_id="O5" value="50.0" lower_limit="33.3" upper_limit="66.7"/>
                    <measurement group_id="O6" value="10.0" lower_limit="3.7" upper_limit="22.1"/>
                    <measurement group_id="O7" value="30.0" lower_limit="18.2" upper_limit="45.5"/>
                    <measurement group_id="O8" value="37.0" lower_limit="22.1" upper_limit="54.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" lower_limit="8.2" upper_limit="31.3"/>
                    <measurement group_id="O2" value="30.0" lower_limit="18.2" upper_limit="45.5"/>
                    <measurement group_id="O3" value="34.4" lower_limit="20.7" upper_limit="50.0"/>
                    <measurement group_id="O4" value="45.2" lower_limit="29.7" upper_limit="60.1"/>
                    <measurement group_id="O5" value="50.0" lower_limit="33.3" upper_limit="66.7"/>
                    <measurement group_id="O6" value="16.7" lower_limit="8.3" upper_limit="30.8"/>
                    <measurement group_id="O7" value="33.3" lower_limit="19.3" upper_limit="49.2"/>
                    <measurement group_id="O8" value="40.7" lower_limit="24.8" upper_limit="58.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Follow-up visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="3.4" upper_limit="20.2"/>
                    <measurement group_id="O2" value="30.0" lower_limit="18.2" upper_limit="45.5"/>
                    <measurement group_id="O3" value="21.9" lower_limit="12.1" upper_limit="36.2"/>
                    <measurement group_id="O4" value="19.4" lower_limit="8.8" upper_limit="32.7"/>
                    <measurement group_id="O5" value="21.4" lower_limit="9.8" upper_limit="36.6"/>
                    <measurement group_id="O6" value="20.0" lower_limit="9.1" upper_limit="33.9"/>
                    <measurement group_id="O7" value="20.0" lower_limit="9.1" upper_limit="33.9"/>
                    <measurement group_id="O8" value="7.4" lower_limit="2.0" upper_limit="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 1: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2450</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>3.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.4</ci_lower_limit>
            <ci_upper_limit>14.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 1: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2575</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>3.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.3</ci_lower_limit>
            <ci_upper_limit>14.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 1: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0087</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>16.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.7</ci_lower_limit>
            <ci_upper_limit>31.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At Week 1: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0392</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>10.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>25.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>At Week 1: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.2</ci_lower_limit>
            <ci_upper_limit>11.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At Week 1: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1528</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>7.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.9</ci_lower_limit>
            <ci_upper_limit>22.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 2: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4989</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.7</ci_lower_limit>
            <ci_upper_limit>15.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 2: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5419</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.6</ci_lower_limit>
            <ci_upper_limit>14.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 2: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1362</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>10.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>26.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At Week 2: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0541</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>15.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>33.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>At Week 2: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3945</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>3.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.0</ci_lower_limit>
            <ci_upper_limit>19.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At Week 2: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0201</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>23.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.9</ci_lower_limit>
            <ci_upper_limit>41.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 3: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1372</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>11.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.4</ci_lower_limit>
            <ci_upper_limit>28.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 3: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3924</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>3.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.6</ci_lower_limit>
            <ci_upper_limit>19.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 3: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0311</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>20.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.4</ci_lower_limit>
            <ci_upper_limit>38.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At Week 3: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0392</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>20.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8</ci_lower_limit>
            <ci_upper_limit>38.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>At Week 3: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1541</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>10.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.2</ci_lower_limit>
            <ci_upper_limit>26.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At Week 3: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0091</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>27.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.8</ci_lower_limit>
            <ci_upper_limit>45.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 4: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2835</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>8.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.5</ci_lower_limit>
            <ci_upper_limit>27.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 4: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2700</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>9.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.7</ci_lower_limit>
            <ci_upper_limit>27.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 4: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0662</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>17.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>36.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At Week 4: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0050</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>31.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.2</ci_lower_limit>
            <ci_upper_limit>50.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>At Week 4: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0302</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>20.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.2</ci_lower_limit>
            <ci_upper_limit>38.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At Week 4: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0091</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>27.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.8</ci_lower_limit>
            <ci_upper_limit>45.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 6: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1561</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>11.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.5</ci_lower_limit>
            <ci_upper_limit>30.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 6: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0753</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>16.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>34.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 6: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0108</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>27.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.7</ci_lower_limit>
            <ci_upper_limit>46.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At Week 6: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0050</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>31.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.2</ci_lower_limit>
            <ci_upper_limit>50.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>At Week 6: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0775</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>16.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>35.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At Week 6: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0243</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>24.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.4</ci_lower_limit>
            <ci_upper_limit>43.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At follow-up visit: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0234</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>20.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.5</ci_lower_limit>
            <ci_upper_limit>38.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At follow-up visit: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1134</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>12.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>29.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At follow-up visit: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1362</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>10.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>26.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At follow-up visit: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1029</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>12.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>29.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>At follow-up visit: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.9</ci_lower_limit>
            <ci_upper_limit>17.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At follow-up visit: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8972</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-12.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-28.8</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Affected Body Surface Area (BSA) at Weeks 1, 2, 3, 4, 6 and Follow-up Visit</title>
        <description>4 body regions were evaluated: head and neck, upper limbs, trunk (including axillae and groin) and lower limbs (including buttocks). Scalp, palms and soles were excluded. BSA was calculated using handprint method. Number of handprints (size of participant's full palmer hand) fitting in the affected area of a body region was estimated. Maximum number of handprints were 10 for head and neck, 20 for upper limbs, 30 for trunk and 40 for lower limbs. Surface area of body region equivalent to 1 handprint: 1 handprint was equal to 10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% for lower limbs. Percent BSA for a body region was calculated as = total number of handprints in a body region * % surface area equivalent to 1 handprint. Overall % BSA for an individual: arithmetic mean of % BSA of all 4 body regions, ranged from 0 to 100%, with higher values representing greater severity of AD.</description>
        <time_frame>Baseline, Weeks 1, 2, 3, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)</time_frame>
        <population>Full analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure and &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream Once Daily (QD)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 0.1% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 0.3% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 1.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 3.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Cream Twice Daily (BID)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 0.3% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841 1.0% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Affected Body Surface Area (BSA) at Weeks 1, 2, 3, 4, 6 and Follow-up Visit</title>
          <description>4 body regions were evaluated: head and neck, upper limbs, trunk (including axillae and groin) and lower limbs (including buttocks). Scalp, palms and soles were excluded. BSA was calculated using handprint method. Number of handprints (size of participant's full palmer hand) fitting in the affected area of a body region was estimated. Maximum number of handprints were 10 for head and neck, 20 for upper limbs, 30 for trunk and 40 for lower limbs. Surface area of body region equivalent to 1 handprint: 1 handprint was equal to 10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% for lower limbs. Percent BSA for a body region was calculated as = total number of handprints in a body region * % surface area equivalent to 1 handprint. Overall % BSA for an individual: arithmetic mean of % BSA of all 4 body regions, ranged from 0 to 100%, with higher values representing greater severity of AD.</description>
          <population>Full analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure and &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="36"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="34"/>
                    <count group_id="O7" value="36"/>
                    <count group_id="O8" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" lower_limit="-12.2" upper_limit="7.4"/>
                    <measurement group_id="O2" value="-2.9" lower_limit="-12.5" upper_limit="6.8"/>
                    <measurement group_id="O3" value="-16.2" lower_limit="-26.2" upper_limit="-6.2"/>
                    <measurement group_id="O4" value="-19.9" lower_limit="-29.6" upper_limit="-10.2"/>
                    <measurement group_id="O5" value="-23.0" lower_limit="-32.8" upper_limit="-13.1"/>
                    <measurement group_id="O6" value="8.5" lower_limit="-8.3" upper_limit="25.3"/>
                    <measurement group_id="O7" value="-16.5" lower_limit="-32.9" upper_limit="-0.1"/>
                    <measurement group_id="O8" value="-17.0" lower_limit="-33.5" upper_limit="-0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="32"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.3" lower_limit="-28.0" upper_limit="-2.6"/>
                    <measurement group_id="O2" value="-7.2" lower_limit="-20.2" upper_limit="5.8"/>
                    <measurement group_id="O3" value="-38.1" lower_limit="-51.0" upper_limit="-25.2"/>
                    <measurement group_id="O4" value="-43.6" lower_limit="-56.5" upper_limit="-30.8"/>
                    <measurement group_id="O5" value="-39.0" lower_limit="-52.1" upper_limit="-26.0"/>
                    <measurement group_id="O6" value="-2.5" lower_limit="-14.0" upper_limit="9.1"/>
                    <measurement group_id="O7" value="-34.2" lower_limit="-45.4" upper_limit="-22.9"/>
                    <measurement group_id="O8" value="-43.1" lower_limit="-54.5" upper_limit="-31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.1" lower_limit="-31.0" upper_limit="-3.1"/>
                    <measurement group_id="O2" value="-13.1" lower_limit="-27.4" upper_limit="1.1"/>
                    <measurement group_id="O3" value="-50.6" lower_limit="-64.4" upper_limit="-36.7"/>
                    <measurement group_id="O4" value="-55.9" lower_limit="-69.7" upper_limit="-42.0"/>
                    <measurement group_id="O5" value="-49.2" lower_limit="-63.2" upper_limit="-35.1"/>
                    <measurement group_id="O6" value="-25.2" lower_limit="-39.2" upper_limit="-11.1"/>
                    <measurement group_id="O7" value="-39.8" lower_limit="-53.0" upper_limit="-26.6"/>
                    <measurement group_id="O8" value="-44.0" lower_limit="-57.1" upper_limit="-30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.9" lower_limit="-39.8" upper_limit="-12.0"/>
                    <measurement group_id="O2" value="-20.1" lower_limit="-34.4" upper_limit="-5.7"/>
                    <measurement group_id="O3" value="-55.8" lower_limit="-69.5" upper_limit="-42.1"/>
                    <measurement group_id="O4" value="-57.9" lower_limit="-71.7" upper_limit="-44.0"/>
                    <measurement group_id="O5" value="-56.7" lower_limit="-70.8" upper_limit="-42.7"/>
                    <measurement group_id="O6" value="-34.7" lower_limit="-46.1" upper_limit="-23.3"/>
                    <measurement group_id="O7" value="-46.4" lower_limit="-56.9" upper_limit="-35.9"/>
                    <measurement group_id="O8" value="-57.7" lower_limit="-68.2" upper_limit="-47.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.6" lower_limit="-38.0" upper_limit="-5.3"/>
                    <measurement group_id="O2" value="-39.4" lower_limit="-56.1" upper_limit="-22.7"/>
                    <measurement group_id="O3" value="-59.4" lower_limit="-75.4" upper_limit="-43.5"/>
                    <measurement group_id="O4" value="-63.6" lower_limit="-79.5" upper_limit="-47.6"/>
                    <measurement group_id="O5" value="-60.3" lower_limit="-76.4" upper_limit="-44.1"/>
                    <measurement group_id="O6" value="-31.2" lower_limit="-42.5" upper_limit="-20.0"/>
                    <measurement group_id="O7" value="-48.9" lower_limit="-59.3" upper_limit="-38.6"/>
                    <measurement group_id="O8" value="-65.0" lower_limit="-75.3" upper_limit="-54.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Follow-up visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="26"/>
                    <count group_id="O6" value="28"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.6" lower_limit="-39.5" upper_limit="-7.6"/>
                    <measurement group_id="O2" value="-24.5" lower_limit="-41.0" upper_limit="-8.0"/>
                    <measurement group_id="O3" value="-42.7" lower_limit="-58.1" upper_limit="-27.2"/>
                    <measurement group_id="O4" value="-37.0" lower_limit="-52.6" upper_limit="-21.4"/>
                    <measurement group_id="O5" value="-55.2" lower_limit="-71.8" upper_limit="-38.6"/>
                    <measurement group_id="O6" value="-26.3" lower_limit="-47.5" upper_limit="-5.2"/>
                    <measurement group_id="O7" value="-31.6" lower_limit="-52.0" upper_limit="-11.3"/>
                    <measurement group_id="O8" value="-24.6" lower_limit="-45.2" upper_limit="-4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 1: Mixed Model Repeated Measure (MMRM) contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4781</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.33</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.2</ci_lower_limit>
            <ci_upper_limit>13.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 1: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0522</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-13.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.47</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.8</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 1: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0187</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-17.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.37</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31.4</ci_lower_limit>
            <ci_upper_limit>-3.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At Week 1: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0080</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-20.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.45</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.5</ci_lower_limit>
            <ci_upper_limit>-6.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>At Week 1: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0401</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-25.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>14.17</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-48.6</ci_lower_limit>
            <ci_upper_limit>-1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At Week 1: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0379</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-25.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>14.25</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-49.2</ci_lower_limit>
            <ci_upper_limit>-1.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 2: MMRM contained fixed factors of treatment, visit(Weeks 1, 2, 3, 4, 6 and follow up), treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7678</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>8.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.01</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.1</ci_lower_limit>
            <ci_upper_limit>26.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 2: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0193</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-22.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.94</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-40.9</ci_lower_limit>
            <ci_upper_limit>-4.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 2:MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0052</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-28.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>10.95</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-46.5</ci_lower_limit>
            <ci_upper_limit>-10.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At Week 2: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0164</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-23.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.03</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.0</ci_lower_limit>
            <ci_upper_limit>-5.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>At Week 2: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-31.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.72</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-47.8</ci_lower_limit>
            <ci_upper_limit>-15.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At Week 2: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-40.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.86</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-57.0</ci_lower_limit>
            <ci_upper_limit>-24.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 3: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6269</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>3.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>12.09</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.1</ci_lower_limit>
            <ci_upper_limit>23.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 3: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0027</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-33.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.87</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-53.1</ci_lower_limit>
            <ci_upper_limit>-13.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 3: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-38.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.89</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-58.5</ci_lower_limit>
            <ci_upper_limit>-19.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At Week 3: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0041</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-32.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>12.00</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51.9</ci_lower_limit>
            <ci_upper_limit>-12.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>At Week 3: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1054</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-14.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.61</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.9</ci_lower_limit>
            <ci_upper_limit>4.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At Week 3: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0542</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-18.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.62</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.1</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 4: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6847</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>5.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>12.12</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.2</ci_lower_limit>
            <ci_upper_limit>25.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 4: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0062</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-29.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.82</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-49.4</ci_lower_limit>
            <ci_upper_limit>-10.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 4: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0040</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-32.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.89</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51.6</ci_lower_limit>
            <ci_upper_limit>-12.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At Week 4: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0054</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-30.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>11.97</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-50.6</ci_lower_limit>
            <ci_upper_limit>-11.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>At Week 4: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1076</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-11.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.35</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.2</ci_lower_limit>
            <ci_upper_limit>3.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At Week 4: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0082</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-23.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.42</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.6</ci_lower_limit>
            <ci_upper_limit>-7.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 6: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1051</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-17.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>14.14</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.2</ci_lower_limit>
            <ci_upper_limit>5.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 6: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0034</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-37.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>13.80</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-60.6</ci_lower_limit>
            <ci_upper_limit>-15.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 6: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0014</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-41.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>13.83</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-64.8</ci_lower_limit>
            <ci_upper_limit>-19.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At Week 6: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0030</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-38.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>13.90</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-61.6</ci_lower_limit>
            <ci_upper_limit>-15.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>At Week 6: MMRM contained fixed factors of treatment, visit(Weeks 1, 2, 3, 4, 6 and follow up), treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0289</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-17.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.22</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-33.0</ci_lower_limit>
            <ci_upper_limit>-2.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At Week 6: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-33.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.27</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-49.2</ci_lower_limit>
            <ci_upper_limit>-18.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At follow-up visit: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4739</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>13.88</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.9</ci_lower_limit>
            <ci_upper_limit>22.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At follow-up visit: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0789</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-19.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>13.43</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-41.3</ci_lower_limit>
            <ci_upper_limit>3.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At follow-up visit: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1611</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-13.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>13.50</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35.7</ci_lower_limit>
            <ci_upper_limit>8.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At follow-up visit: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0124</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-31.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>13.94</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.7</ci_lower_limit>
            <ci_upper_limit>-8.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>At follow-up visit: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3828</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-5.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>17.68</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.7</ci_lower_limit>
            <ci_upper_limit>24.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At follow-up visit: MMRM contained fixed factors of treatment, visit, treatment-by-visit interaction and baseline value.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5383</p_value>
            <method>Mixed Model Repeated Measure</method>
            <param_type>LS Mean difference</param_type>
            <param_value>1.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>17.80</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.9</ci_lower_limit>
            <ci_upper_limit>31.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving &gt;=75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation</title>
        <description>EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions(head and neck, upper limbs, trunk [including axillae and groin] and lower limbs [including buttocks]) on4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each 4 body region: 0 (0%), 1 (&gt;0 to &lt;10%), 2 (10 to &lt;30%), 3 (30 to &lt;50%), 4 (50 to &lt;70%), 5 (70 to &lt;90%) and 6 (90 to 100%). Total EASI score =0.1*Ah*(Eh+Ih+Exh+Lh) + 0.2*Au*(Eu+Iu+ExU+Lu) + 0.3*At*(Et+It+Ext+Lt) + 0.4*Al*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.</description>
        <time_frame>Baseline, Weeks 1, 2, 3, 4 and 6</time_frame>
        <population>Full analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. NRI method: participants with missing values were considered to be non-responders.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream Once Daily (QD)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 0.1% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 0.3% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 1.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 3.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Cream Twice Daily (BID)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 0.3% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841 1.0% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving &gt;=75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline at Weeks 1, 2, 3, 4 and 6: Non-responder Imputation</title>
          <description>EASI evaluates severity of participant's AD (excluded scalp, palms, soles) based on severity of AD clinical signs and % of body surface area (BSA) affected. Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions(head and neck, upper limbs, trunk [including axillae and groin] and lower limbs [including buttocks]) on4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based upon % BSA with AD in each 4 body region: 0 (0%), 1 (&gt;0 to &lt;10%), 2 (10 to &lt;30%), 3 (30 to &lt;50%), 4 (50 to &lt;70%), 5 (70 to &lt;90%) and 6 (90 to 100%). Total EASI score =0.1*Ah*(Eh+Ih+Exh+Lh) + 0.2*Au*(Eu+Iu+ExU+Lu) + 0.3*At*(Et+It+Ext+Lt) + 0.4*Al*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, higher scores = greater severity of AD.</description>
          <population>Full analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. NRI method: participants with missing values were considered to be non-responders.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="36"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="1.4" upper_limit="15.5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="7.3"/>
                    <measurement group_id="O3" value="19.4" lower_limit="10.7" upper_limit="32.8"/>
                    <measurement group_id="O4" value="5.4" lower_limit="1.4" upper_limit="15.5"/>
                    <measurement group_id="O5" value="16.7" lower_limit="7.5" upper_limit="30.2"/>
                    <measurement group_id="O6" value="0.0" lower_limit="0.0" upper_limit="7.5"/>
                    <measurement group_id="O7" value="13.9" lower_limit="6.9" upper_limit="25.4"/>
                    <measurement group_id="O8" value="21.6" lower_limit="11.2" upper_limit="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" lower_limit="3.0" upper_limit="18.5"/>
                    <measurement group_id="O2" value="10.8" lower_limit="4.8" upper_limit="22.2"/>
                    <measurement group_id="O3" value="27.8" lower_limit="15.9" upper_limit="40.9"/>
                    <measurement group_id="O4" value="24.3" lower_limit="14.5" upper_limit="37.0"/>
                    <measurement group_id="O5" value="38.9" lower_limit="25.4" upper_limit="53.0"/>
                    <measurement group_id="O6" value="13.9" lower_limit="6.9" upper_limit="25.4"/>
                    <measurement group_id="O7" value="25.0" lower_limit="14.9" upper_limit="38.0"/>
                    <measurement group_id="O8" value="32.4" lower_limit="20.6" upper_limit="46.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="1.4" upper_limit="15.5"/>
                    <measurement group_id="O2" value="16.2" lower_limit="7.3" upper_limit="29.3"/>
                    <measurement group_id="O3" value="36.1" lower_limit="22.9" upper_limit="50.0"/>
                    <measurement group_id="O4" value="43.2" lower_limit="29.3" upper_limit="56.8"/>
                    <measurement group_id="O5" value="41.7" lower_limit="29.0" upper_limit="56.0"/>
                    <measurement group_id="O6" value="19.4" lower_limit="10.7" upper_limit="32.8"/>
                    <measurement group_id="O7" value="19.4" lower_limit="10.7" upper_limit="32.8"/>
                    <measurement group_id="O8" value="43.2" lower_limit="29.3" upper_limit="56.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3" lower_limit="14.5" upper_limit="37.0"/>
                    <measurement group_id="O2" value="21.6" lower_limit="11.2" upper_limit="34.3"/>
                    <measurement group_id="O3" value="38.9" lower_limit="25.4" upper_limit="53.0"/>
                    <measurement group_id="O4" value="43.2" lower_limit="29.3" upper_limit="56.8"/>
                    <measurement group_id="O5" value="50.0" lower_limit="35.3" upper_limit="64.7"/>
                    <measurement group_id="O6" value="22.2" lower_limit="11.6" upper_limit="35.3"/>
                    <measurement group_id="O7" value="36.1" lower_limit="22.9" upper_limit="50.0"/>
                    <measurement group_id="O8" value="48.6" lower_limit="34.3" upper_limit="63.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1" lower_limit="22.2" upper_limit="49.3"/>
                    <measurement group_id="O2" value="32.4" lower_limit="20.6" upper_limit="46.4"/>
                    <measurement group_id="O3" value="52.8" lower_limit="38.0" upper_limit="67.2"/>
                    <measurement group_id="O4" value="54.1" lower_limit="40.2" upper_limit="68.2"/>
                    <measurement group_id="O5" value="50.0" lower_limit="35.3" upper_limit="64.7"/>
                    <measurement group_id="O6" value="16.7" lower_limit="7.5" upper_limit="30.2"/>
                    <measurement group_id="O7" value="36.1" lower_limit="22.9" upper_limit="50.0"/>
                    <measurement group_id="O8" value="51.4" lower_limit="37.0" upper_limit="65.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 1: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8964</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-5.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.1</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 1: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0391</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>14.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0</ci_lower_limit>
            <ci_upper_limit>28.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 1: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.8</ci_lower_limit>
            <ci_upper_limit>10.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At Week 1: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0708</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>11.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>25.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>At Week 1: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0122</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>13.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.7</ci_lower_limit>
            <ci_upper_limit>27.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At Week 1: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0016</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>21.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.0</ci_lower_limit>
            <ci_upper_limit>35.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 2: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3950</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>2.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.8</ci_lower_limit>
            <ci_upper_limit>16.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 2: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0173</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>19.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.2</ci_lower_limit>
            <ci_upper_limit>35.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 2: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0327</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>16.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.4</ci_lower_limit>
            <ci_upper_limit>31.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At Week 2: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>30.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.2</ci_lower_limit>
            <ci_upper_limit>46.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>At Week 2: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1348</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>11.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>27.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At Week 2: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0328</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>18.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.5</ci_lower_limit>
            <ci_upper_limit>34.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 3: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0769</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>10.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>24.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 3: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>30.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.2</ci_lower_limit>
            <ci_upper_limit>46.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 3: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>37.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>22.1</ci_lower_limit>
            <ci_upper_limit>53.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At Week 3: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>36.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>19.7</ci_lower_limit>
            <ci_upper_limit>51.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>At Week 3: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0000</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.5</ci_lower_limit>
            <ci_upper_limit>16.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At Week 3: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0173</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>23.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.5</ci_lower_limit>
            <ci_upper_limit>41.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 4: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5663</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-2.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.9</ci_lower_limit>
            <ci_upper_limit>14.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 4: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1243</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>14.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.8</ci_lower_limit>
            <ci_upper_limit>32.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 4: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0460</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>18.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>36.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At Week 4: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0130</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>25.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.8</ci_lower_limit>
            <ci_upper_limit>43.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>At Week 4: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1194</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>13.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.2</ci_lower_limit>
            <ci_upper_limit>31.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At Week 4: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0097</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>26.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.5</ci_lower_limit>
            <ci_upper_limit>44.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 6: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5556</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-2.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.0</ci_lower_limit>
            <ci_upper_limit>16.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 6: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0761</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>17.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>36.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 6: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0583</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>18.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>37.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>At Week 6: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1245</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>14.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.0</ci_lower_limit>
            <ci_upper_limit>33.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>At Week 6: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0382</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>19.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.5</ci_lower_limit>
            <ci_upper_limit>36.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>At Week 6: Risk difference = difference in percentage of participants.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0011</p_value>
            <method>Chan and Zhang Exact Method</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>34.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.2</ci_lower_limit>
            <ci_upper_limit>51.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. Treatment-emergent were events between first dose of investigational product and up to 28 days after the last dose of investigational product that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and all non-SAEs.</description>
        <time_frame>Baseline (Day 1) up to at least 28 days after last dose of study drug (approximately up to Week 11)</time_frame>
        <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream Once Daily (QD)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 0.1% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 0.3% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 1.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 3.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Cream Twice Daily (BID)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 0.3% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841 1.0% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; medically important events. Treatment-emergent were events between first dose of investigational product and up to 28 days after the last dose of investigational product that were absent before treatment or that worsened relative to pretreatment state. AEs included both SAEs and all non-SAEs.</description>
          <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="36"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="17"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Pre-defined Criteria For Vital Signs</title>
        <description>Pre-defined criteria included: 1) Diastolic blood pressure (DBP), a) sitting DBP: change of &gt;= 20 millimeter of mercury (mmHg) increase, b) sitting DBP: change of &gt;=20mmHg decrease, c) supine DBP: less than (&lt;) 50 mmHg, d) supine DBP: change of &gt;= 20mmHg increase, e) supine DBP: change of &gt;= 20mmHg decrease; 2) Systolic blood pressure (SBP), a) sitting SBP: &lt;90 mmHg, b) sitting SBP: change of &gt;=30mmHg increase, c) sitting SBP: change of &gt;=30mmHg decrease, d) supine SBP: change of &gt;=30mmHg increase, e) supine SBP: change of &gt;=30mmHg decrease and f) Supine SBP: value &lt;90mmHg.</description>
        <time_frame>Baseline up to Week 6</time_frame>
        <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure and &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream Once Daily (QD)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 0.1% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 0.3% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 1.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 3.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Cream Twice Daily (BID)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 0.3% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841 1.0% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pre-defined Criteria For Vital Signs</title>
          <description>Pre-defined criteria included: 1) Diastolic blood pressure (DBP), a) sitting DBP: change of &gt;= 20 millimeter of mercury (mmHg) increase, b) sitting DBP: change of &gt;=20mmHg decrease, c) supine DBP: less than (&lt;) 50 mmHg, d) supine DBP: change of &gt;= 20mmHg increase, e) supine DBP: change of &gt;= 20mmHg decrease; 2) Systolic blood pressure (SBP), a) sitting SBP: &lt;90 mmHg, b) sitting SBP: change of &gt;=30mmHg increase, c) sitting SBP: change of &gt;=30mmHg decrease, d) supine SBP: change of &gt;=30mmHg increase, e) supine SBP: change of &gt;=30mmHg decrease and f) Supine SBP: value &lt;90mmHg.</description>
          <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure and &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="18"/>
                <count group_id="O5" value="21"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="22"/>
                <count group_id="O8" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sitting DBP: Change &gt;= 20 mm Hg increase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting DBP: Change &gt;= 20mmHg decrease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine DBP: Value &lt;50 mmHg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="19"/>
                    <count group_id="O7" value="22"/>
                    <count group_id="O8" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine DBP: Change &gt;= 20mmHg increase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="19"/>
                    <count group_id="O7" value="22"/>
                    <count group_id="O8" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine DBP: Change &gt;= 20mmHg decrease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="19"/>
                    <count group_id="O7" value="22"/>
                    <count group_id="O8" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting SBP: &lt;90mmHg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting SBP: change &gt;= 30mmHg increase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting SBP: change &gt;= 30mmHg decrease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="12"/>
                    <count group_id="O8" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine SBP: Change &gt;= 30mmHg increase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="19"/>
                    <count group_id="O7" value="22"/>
                    <count group_id="O8" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine SBP: Change &gt;= 30mmHg decrease</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="19"/>
                    <count group_id="O7" value="22"/>
                    <count group_id="O8" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine SBP: Value &lt;90mmHg</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="19"/>
                    <count group_id="O7" value="22"/>
                    <count group_id="O8" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Laboratory Abnormalities</title>
        <description>Hemoglobin (HGB),hematocrit,erythrocytes (ery.),HDL cholesterol (chl.)&lt;0.8*lower limit of normal(LLN);reticulocytes (ret.), ret./ery. (%)&lt;0.5*LLN,&gt;1.5*upper limit of normal (ULN);ery. mean corpuscular (EMC) volume,EMC HGB,EMC HGB concentration,potassium,chloride,calcium,bicarbonate&lt;0.9*LLN,&gt;1.1*ULN;platelets&lt;0.5*LLN,&gt;1.75*ULN;leukocytes (leu.),glucose&lt;0.6*LLN,&gt;1.5*ULN;lymphocytes (lym.), lym./leu.(%), neutrophils (neu.), neu./leu. (%), protein,albumin &lt;0.8*LLN,&gt;1.2*ULN;basophils (bas.), bas./leu.(%), eosinophils (eos.), eos./leu., monocytes (mon.), mon./leu.(%), urate &gt;1.2*ULN;bilirubin (total, direct, indirect)&gt;1.5*ULN;aspartate/alanine aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase&gt;3.0*ULN;urea nitrogen, creatinine, triglycerides, chl.&gt;1.3*ULN; sodium &lt;0.95*LLN,&gt;1.05*ULN; creatine kinase &gt;2.0*ULN;Urine: pH&lt;4.5,&gt;8;glucose, ketones, protein, HGB, urobilinogen,bilirubin,nitrite,leukocyte esterase&gt;=1;ery., leu.&gt;= 20;hyaline casts&gt;1;bacteria&gt;20.</description>
        <time_frame>Baseline (Day 1) up to at least 28 days after last dose of study drug (approximately up to Week 11)</time_frame>
        <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream Once Daily (QD)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 0.1% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 0.3% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 1.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 3.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Cream Twice Daily (BID)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 0.3% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841 1.0% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Abnormalities</title>
          <description>Hemoglobin (HGB),hematocrit,erythrocytes (ery.),HDL cholesterol (chl.)&lt;0.8*lower limit of normal(LLN);reticulocytes (ret.), ret./ery. (%)&lt;0.5*LLN,&gt;1.5*upper limit of normal (ULN);ery. mean corpuscular (EMC) volume,EMC HGB,EMC HGB concentration,potassium,chloride,calcium,bicarbonate&lt;0.9*LLN,&gt;1.1*ULN;platelets&lt;0.5*LLN,&gt;1.75*ULN;leukocytes (leu.),glucose&lt;0.6*LLN,&gt;1.5*ULN;lymphocytes (lym.), lym./leu.(%), neutrophils (neu.), neu./leu. (%), protein,albumin &lt;0.8*LLN,&gt;1.2*ULN;basophils (bas.), bas./leu.(%), eosinophils (eos.), eos./leu., monocytes (mon.), mon./leu.(%), urate &gt;1.2*ULN;bilirubin (total, direct, indirect)&gt;1.5*ULN;aspartate/alanine aminotransferase, gamma glutamyl transferase, lactate dehydrogenase, alkaline phosphatase&gt;3.0*ULN;urea nitrogen, creatinine, triglycerides, chl.&gt;1.3*ULN; sodium &lt;0.95*LLN,&gt;1.05*ULN; creatine kinase &gt;2.0*ULN;Urine: pH&lt;4.5,&gt;8;glucose, ketones, protein, HGB, urobilinogen,bilirubin,nitrite,leukocyte esterase&gt;=1;ery., leu.&gt;= 20;hyaline casts&gt;1;bacteria&gt;20.</description>
          <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="35"/>
                <count group_id="O6" value="36"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="21"/>
                    <measurement group_id="O7" value="24"/>
                    <measurement group_id="O8" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Findings</title>
        <description>Clinically significant ECG criteria included PR interval: value greater than (&gt;) 280 millisecond (msec), percentage change greater than equal to (&gt;=) 25/50 percentage, QRS interval: value &gt;120 msec, percentage change &gt;= 50% and QT interval corrected using the Fridericia's formula (QTCF) value 450 msec and 30&lt;=change&lt;60.</description>
        <time_frame>Baseline up to Week 6</time_frame>
        <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream Once Daily (QD)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 0.1% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 0.3% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 1.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 3.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Cream Twice Daily (BID)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 0.3% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841 1.0% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Findings</title>
          <description>Clinically significant ECG criteria included PR interval: value greater than (&gt;) 280 millisecond (msec), percentage change greater than equal to (&gt;=) 25/50 percentage, QRS interval: value &gt;120 msec, percentage change &gt;= 50% and QT interval corrected using the Fridericia's formula (QTCF) value 450 msec and 30&lt;=change&lt;60.</description>
          <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR interval : value &gt;280 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval : %change&gt;=25/50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval: value &gt;120 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval: %Change&gt;=50%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTCF: 450 msec</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTCF: 30&lt;=Change&lt;60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinical Chemistry-Lactate Dehydrogenase Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit</title>
        <time_frame>Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)</time_frame>
        <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure and &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream Once Daily (QD)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 0.1% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 0.3% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 1.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 3.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Cream Twice Daily (BID)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 0.3% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841 1.0% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Chemistry-Lactate Dehydrogenase Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit</title>
          <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure and &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
          <units>Units per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="32"/>
                <count group_id="O7" value="34"/>
                <count group_id="O8" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="32"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="30"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="32"/>
                    <count group_id="O7" value="34"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="25.99"/>
                    <measurement group_id="O2" value="-7.4" spread="30.20"/>
                    <measurement group_id="O3" value="-5.3" spread="16.99"/>
                    <measurement group_id="O4" value="-9.3" spread="22.65"/>
                    <measurement group_id="O5" value="-18.4" spread="33.42"/>
                    <measurement group_id="O6" value="-8.0" spread="34.51"/>
                    <measurement group_id="O7" value="-8.0" spread="19.37"/>
                    <measurement group_id="O8" value="-4.3" spread="29.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="28"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" spread="21.56"/>
                    <measurement group_id="O2" value="-7.8" spread="27.99"/>
                    <measurement group_id="O3" value="-1.9" spread="18.18"/>
                    <measurement group_id="O4" value="-8.8" spread="23.70"/>
                    <measurement group_id="O5" value="-15.8" spread="42.19"/>
                    <measurement group_id="O6" value="-0.3" spread="22.81"/>
                    <measurement group_id="O7" value="-8.0" spread="22.31"/>
                    <measurement group_id="O8" value="-4.9" spread="24.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="27"/>
                    <count group_id="O8" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" spread="23.93"/>
                    <measurement group_id="O2" value="-5.4" spread="22.87"/>
                    <measurement group_id="O3" value="-9.3" spread="19.61"/>
                    <measurement group_id="O4" value="-12.1" spread="28.54"/>
                    <measurement group_id="O5" value="-16.3" spread="33.97"/>
                    <measurement group_id="O6" value="-1.0" spread="29.29"/>
                    <measurement group_id="O7" value="-19.5" spread="19.94"/>
                    <measurement group_id="O8" value="-3.7" spread="24.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="28"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" spread="18.25"/>
                    <measurement group_id="O2" value="-8.1" spread="32.02"/>
                    <measurement group_id="O3" value="-1.5" spread="32.42"/>
                    <measurement group_id="O4" value="-6.4" spread="28.53"/>
                    <measurement group_id="O5" value="-18.2" spread="33.86"/>
                    <measurement group_id="O6" value="-9.7" spread="20.68"/>
                    <measurement group_id="O7" value="-11.2" spread="22.34"/>
                    <measurement group_id="O8" value="-7.0" spread="24.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at follow-up visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="30"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.3" spread="24.82"/>
                    <measurement group_id="O2" value="-12.0" spread="28.83"/>
                    <measurement group_id="O3" value="4.0" spread="43.45"/>
                    <measurement group_id="O4" value="-2.7" spread="26.27"/>
                    <measurement group_id="O5" value="-15.1" spread="38.23"/>
                    <measurement group_id="O6" value="-11.3" spread="29.39"/>
                    <measurement group_id="O7" value="-13.3" spread="25.37"/>
                    <measurement group_id="O8" value="0.2" spread="16.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinical Chemistry- Protein and Albumin Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit</title>
        <time_frame>Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)</time_frame>
        <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure and &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream Once Daily (QD)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 0.1% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 0.3% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 1.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 3.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Cream Twice Daily (BID)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 0.3% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841 1.0% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Chemistry- Protein and Albumin Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit</title>
          <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure and &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
          <units>Gram per deciliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="36"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Protein: change at week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="34"/>
                    <count group_id="O7" value="36"/>
                    <count group_id="O8" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.439"/>
                    <measurement group_id="O2" value="-0.04" spread="0.294"/>
                    <measurement group_id="O3" value="-0.14" spread="0.433"/>
                    <measurement group_id="O4" value="-0.04" spread="0.264"/>
                    <measurement group_id="O5" value="-0.03" spread="0.421"/>
                    <measurement group_id="O6" value="-0.10" spread="0.360"/>
                    <measurement group_id="O7" value="-0.01" spread="0.344"/>
                    <measurement group_id="O8" value="-0.02" spread="0.301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein:change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.383"/>
                    <measurement group_id="O2" value="0.03" spread="0.303"/>
                    <measurement group_id="O3" value="-0.18" spread="0.402"/>
                    <measurement group_id="O4" value="-0.01" spread="0.275"/>
                    <measurement group_id="O5" value="0.01" spread="0.561"/>
                    <measurement group_id="O6" value="0.02" spread="0.503"/>
                    <measurement group_id="O7" value="-0.04" spread="0.286"/>
                    <measurement group_id="O8" value="-0.10" spread="0.299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein: change at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.380"/>
                    <measurement group_id="O2" value="0.07" spread="0.315"/>
                    <measurement group_id="O3" value="-0.08" spread="0.429"/>
                    <measurement group_id="O4" value="-0.03" spread="0.341"/>
                    <measurement group_id="O5" value="-0.04" spread="0.465"/>
                    <measurement group_id="O6" value="-0.18" spread="0.292"/>
                    <measurement group_id="O7" value="-0.15" spread="0.242"/>
                    <measurement group_id="O8" value="0.03" spread="0.280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.403"/>
                    <measurement group_id="O2" value="0.13" spread="0.379"/>
                    <measurement group_id="O3" value="-0.19" spread="0.452"/>
                    <measurement group_id="O4" value="0.01" spread="0.368"/>
                    <measurement group_id="O5" value="-0.03" spread="0.405"/>
                    <measurement group_id="O6" value="-0.10" spread="0.424"/>
                    <measurement group_id="O7" value="-0.09" spread="0.368"/>
                    <measurement group_id="O8" value="-0.09" spread="0.310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein: change at follow-up visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="31"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.341"/>
                    <measurement group_id="O2" value="0.05" spread="0.457"/>
                    <measurement group_id="O3" value="-0.15" spread="0.481"/>
                    <measurement group_id="O4" value="-0.04" spread="0.404"/>
                    <measurement group_id="O5" value="0.03" spread="0.481"/>
                    <measurement group_id="O6" value="-0.18" spread="0.471"/>
                    <measurement group_id="O7" value="-0.09" spread="0.398"/>
                    <measurement group_id="O8" value="0.02" spread="0.299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin:change at week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="34"/>
                    <count group_id="O7" value="36"/>
                    <count group_id="O8" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.269"/>
                    <measurement group_id="O2" value="-0.05" spread="0.205"/>
                    <measurement group_id="O3" value="-0.10" spread="0.283"/>
                    <measurement group_id="O4" value="-0.02" spread="0.177"/>
                    <measurement group_id="O5" value="0.00" spread="0.256"/>
                    <measurement group_id="O6" value="-0.05" spread="0.218"/>
                    <measurement group_id="O7" value="-0.03" spread="0.246"/>
                    <measurement group_id="O8" value="0.00" spread="0.169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin:change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.235"/>
                    <measurement group_id="O2" value="0.02" spread="0.201"/>
                    <measurement group_id="O3" value="-0.10" spread="0.256"/>
                    <measurement group_id="O4" value="-0.02" spread="0.204"/>
                    <measurement group_id="O5" value="-0.01" spread="0.283"/>
                    <measurement group_id="O6" value="0.02" spread="0.266"/>
                    <measurement group_id="O7" value="-0.03" spread="0.174"/>
                    <measurement group_id="O8" value="-0.06" spread="0.202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin: change at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.245"/>
                    <measurement group_id="O2" value="0.07" spread="0.172"/>
                    <measurement group_id="O3" value="-0.08" spread="0.285"/>
                    <measurement group_id="O4" value="0.01" spread="0.239"/>
                    <measurement group_id="O5" value="0.04" spread="0.292"/>
                    <measurement group_id="O6" value="-0.10" spread="0.232"/>
                    <measurement group_id="O7" value="-0.08" spread="0.180"/>
                    <measurement group_id="O8" value="0.03" spread="0.224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin:change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.259"/>
                    <measurement group_id="O2" value="0.08" spread="0.245"/>
                    <measurement group_id="O3" value="-0.14" spread="0.333"/>
                    <measurement group_id="O4" value="-0.02" spread="0.269"/>
                    <measurement group_id="O5" value="-0.00" spread="0.218"/>
                    <measurement group_id="O6" value="-0.03" spread="0.252"/>
                    <measurement group_id="O7" value="-0.07" spread="0.244"/>
                    <measurement group_id="O8" value="-0.05" spread="0.227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin: change at follow-up visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="31"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.247"/>
                    <measurement group_id="O2" value="0.10" spread="0.260"/>
                    <measurement group_id="O3" value="-0.09" spread="0.277"/>
                    <measurement group_id="O4" value="-0.04" spread="0.295"/>
                    <measurement group_id="O5" value="-0.01" spread="0.346"/>
                    <measurement group_id="O6" value="-0.09" spread="0.262"/>
                    <measurement group_id="O7" value="-0.02" spread="0.211"/>
                    <measurement group_id="O8" value="0.06" spread="0.181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinical Chemistry- Urea Nitrogen, Urate, Calcium and Glucose Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit</title>
        <time_frame>Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)</time_frame>
        <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure and &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream Once Daily (QD)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 0.1% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 0.3% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 1.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 3.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Cream Twice Daily (BID)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 0.3% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841 1.0% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Chemistry- Urea Nitrogen, Urate, Calcium and Glucose Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit</title>
          <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure and &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
          <units>Microgram per deciliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Urea nitrogen: change at week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="34"/>
                    <count group_id="O7" value="36"/>
                    <count group_id="O8" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="4.57"/>
                    <measurement group_id="O2" value="0.6" spread="3.04"/>
                    <measurement group_id="O3" value="0.1" spread="3.12"/>
                    <measurement group_id="O4" value="1.0" spread="3.19"/>
                    <measurement group_id="O5" value="1.0" spread="3.05"/>
                    <measurement group_id="O6" value="0.2" spread="2.19"/>
                    <measurement group_id="O7" value="0.4" spread="3.38"/>
                    <measurement group_id="O8" value="-0.1" spread="2.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea nitrogen: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="3.89"/>
                    <measurement group_id="O2" value="0.0" spread="2.71"/>
                    <measurement group_id="O3" value="0.6" spread="3.54"/>
                    <measurement group_id="O4" value="0.9" spread="3.18"/>
                    <measurement group_id="O5" value="0.5" spread="3.63"/>
                    <measurement group_id="O6" value="0.6" spread="4.19"/>
                    <measurement group_id="O7" value="0.8" spread="2.99"/>
                    <measurement group_id="O8" value="0.4" spread="3.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea nitrogen: change at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="3.39"/>
                    <measurement group_id="O2" value="0.0" spread="3.04"/>
                    <measurement group_id="O3" value="-0.0" spread="2.67"/>
                    <measurement group_id="O4" value="1.4" spread="3.06"/>
                    <measurement group_id="O5" value="0.5" spread="3.84"/>
                    <measurement group_id="O6" value="-0.7" spread="2.96"/>
                    <measurement group_id="O7" value="1.3" spread="2.81"/>
                    <measurement group_id="O8" value="-0.2" spread="3.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea nitrogen: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="2.84"/>
                    <measurement group_id="O2" value="-0.2" spread="3.11"/>
                    <measurement group_id="O3" value="-0.6" spread="3.61"/>
                    <measurement group_id="O4" value="0.9" spread="3.27"/>
                    <measurement group_id="O5" value="0.3" spread="3.82"/>
                    <measurement group_id="O6" value="-0.8" spread="3.24"/>
                    <measurement group_id="O7" value="0.2" spread="3.52"/>
                    <measurement group_id="O8" value="-0.4" spread="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea nitrogen: change at follow-up visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="31"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="3.17"/>
                    <measurement group_id="O2" value="-0.3" spread="3.13"/>
                    <measurement group_id="O3" value="0.4" spread="2.60"/>
                    <measurement group_id="O4" value="1.2" spread="4.22"/>
                    <measurement group_id="O5" value="0.2" spread="2.87"/>
                    <measurement group_id="O6" value="0.8" spread="3.78"/>
                    <measurement group_id="O7" value="0.5" spread="3.42"/>
                    <measurement group_id="O8" value="0.1" spread="3.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urate:change at week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="34"/>
                    <count group_id="O7" value="36"/>
                    <count group_id="O8" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.807"/>
                    <measurement group_id="O2" value="0.01" spread="0.606"/>
                    <measurement group_id="O3" value="0.16" spread="0.678"/>
                    <measurement group_id="O4" value="-0.01" spread="0.561"/>
                    <measurement group_id="O5" value="0.00" spread="0.739"/>
                    <measurement group_id="O6" value="0.05" spread="0.661"/>
                    <measurement group_id="O7" value="-0.02" spread="0.704"/>
                    <measurement group_id="O8" value="-0.14" spread="0.890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urate: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.990"/>
                    <measurement group_id="O2" value="-0.11" spread="0.655"/>
                    <measurement group_id="O3" value="0.12" spread="0.617"/>
                    <measurement group_id="O4" value="-0.03" spread="0.649"/>
                    <measurement group_id="O5" value="-0.15" spread="0.842"/>
                    <measurement group_id="O6" value="0.27" spread="1.025"/>
                    <measurement group_id="O7" value="-0.03" spread="0.718"/>
                    <measurement group_id="O8" value="-0.37" spread="1.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urate: change at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.497"/>
                    <measurement group_id="O2" value="0.14" spread="0.731"/>
                    <measurement group_id="O3" value="0.06" spread="0.756"/>
                    <measurement group_id="O4" value="-0.06" spread="0.621"/>
                    <measurement group_id="O5" value="-0.14" spread="0.856"/>
                    <measurement group_id="O6" value="0.22" spread="0.806"/>
                    <measurement group_id="O7" value="-0.21" spread="0.663"/>
                    <measurement group_id="O8" value="-0.16" spread="0.713"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urate: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.728"/>
                    <measurement group_id="O2" value="0.07" spread="0.984"/>
                    <measurement group_id="O3" value="-0.02" spread="0.831"/>
                    <measurement group_id="O4" value="0.06" spread="0.630"/>
                    <measurement group_id="O5" value="-0.02" spread="0.649"/>
                    <measurement group_id="O6" value="0.06" spread="0.534"/>
                    <measurement group_id="O7" value="-0.11" spread="0.827"/>
                    <measurement group_id="O8" value="-0.21" spread="1.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urate: change at follow- up visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="31"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.721"/>
                    <measurement group_id="O2" value="-0.33" spread="0.753"/>
                    <measurement group_id="O3" value="0.05" spread="0.763"/>
                    <measurement group_id="O4" value="-0.21" spread="0.554"/>
                    <measurement group_id="O5" value="-0.02" spread="0.810"/>
                    <measurement group_id="O6" value="0.02" spread="0.590"/>
                    <measurement group_id="O7" value="-0.08" spread="0.677"/>
                    <measurement group_id="O8" value="-0.20" spread="0.989"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium:change at week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="34"/>
                    <count group_id="O7" value="36"/>
                    <count group_id="O8" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.419"/>
                    <measurement group_id="O2" value="0.01" spread="0.259"/>
                    <measurement group_id="O3" value="-0.06" spread="0.377"/>
                    <measurement group_id="O4" value="-0.02" spread="0.248"/>
                    <measurement group_id="O5" value="0.07" spread="0.386"/>
                    <measurement group_id="O6" value="-0.02" spread="0.303"/>
                    <measurement group_id="O7" value="-0.01" spread="0.295"/>
                    <measurement group_id="O8" value="0.09" spread="0.318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="0.417"/>
                    <measurement group_id="O2" value="0.00" spread="0.268"/>
                    <measurement group_id="O3" value="-0.10" spread="0.362"/>
                    <measurement group_id="O4" value="0.05" spread="0.296"/>
                    <measurement group_id="O5" value="0.07" spread="0.423"/>
                    <measurement group_id="O6" value="0.03" spread="0.389"/>
                    <measurement group_id="O7" value="-0.10" spread="0.293"/>
                    <measurement group_id="O8" value="-0.01" spread="0.244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium: change at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.354"/>
                    <measurement group_id="O2" value="0.11" spread="0.329"/>
                    <measurement group_id="O3" value="-0.07" spread="0.345"/>
                    <measurement group_id="O4" value="0.05" spread="0.272"/>
                    <measurement group_id="O5" value="0.00" spread="0.376"/>
                    <measurement group_id="O6" value="-0.08" spread="0.309"/>
                    <measurement group_id="O7" value="-0.03" spread="0.257"/>
                    <measurement group_id="O8" value="0.10" spread="0.341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.355"/>
                    <measurement group_id="O2" value="0.10" spread="0.303"/>
                    <measurement group_id="O3" value="-0.21" spread="0.393"/>
                    <measurement group_id="O4" value="0.03" spread="0.315"/>
                    <measurement group_id="O5" value="0.00" spread="0.397"/>
                    <measurement group_id="O6" value="-0.05" spread="0.335"/>
                    <measurement group_id="O7" value="-0.05" spread="0.464"/>
                    <measurement group_id="O8" value="-0.04" spread="0.337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium: change at follow-up visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="31"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.317"/>
                    <measurement group_id="O2" value="-0.01" spread="0.345"/>
                    <measurement group_id="O3" value="-0.08" spread="0.409"/>
                    <measurement group_id="O4" value="0.00" spread="0.323"/>
                    <measurement group_id="O5" value="0.10" spread="0.441"/>
                    <measurement group_id="O6" value="-0.05" spread="0.419"/>
                    <measurement group_id="O7" value="0.01" spread="0.378"/>
                    <measurement group_id="O8" value="0.05" spread="0.356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose:change at week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                    <count group_id="O7" value="36"/>
                    <count group_id="O8" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="8.73"/>
                    <measurement group_id="O2" value="5.7" spread="13.97"/>
                    <measurement group_id="O3" value="3.4" spread="14.62"/>
                    <measurement group_id="O4" value="4.5" spread="8.60"/>
                    <measurement group_id="O5" value="4.4" spread="16.14"/>
                    <measurement group_id="O6" value="4.5" spread="29.90"/>
                    <measurement group_id="O7" value="5.6" spread="13.14"/>
                    <measurement group_id="O8" value="3.3" spread="13.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" spread="23.71"/>
                    <measurement group_id="O2" value="1.2" spread="17.34"/>
                    <measurement group_id="O3" value="0.6" spread="10.97"/>
                    <measurement group_id="O4" value="3.2" spread="12.63"/>
                    <measurement group_id="O5" value="3.1" spread="10.00"/>
                    <measurement group_id="O6" value="-1.9" spread="13.51"/>
                    <measurement group_id="O7" value="7.9" spread="16.67"/>
                    <measurement group_id="O8" value="2.7" spread="18.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose: change at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="15.60"/>
                    <measurement group_id="O2" value="0.5" spread="12.50"/>
                    <measurement group_id="O3" value="-1.2" spread="15.86"/>
                    <measurement group_id="O4" value="4.5" spread="13.99"/>
                    <measurement group_id="O5" value="2.8" spread="20.20"/>
                    <measurement group_id="O6" value="1.3" spread="24.01"/>
                    <measurement group_id="O7" value="10.7" spread="26.13"/>
                    <measurement group_id="O8" value="3.4" spread="18.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="9.19"/>
                    <measurement group_id="O2" value="2.4" spread="17.55"/>
                    <measurement group_id="O3" value="-1.7" spread="10.62"/>
                    <measurement group_id="O4" value="2.1" spread="13.80"/>
                    <measurement group_id="O5" value="-0.5" spread="9.77"/>
                    <measurement group_id="O6" value="-3.4" spread="16.37"/>
                    <measurement group_id="O7" value="4.3" spread="12.23"/>
                    <measurement group_id="O8" value="1.5" spread="12.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose: change at follow -up visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="31"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="11.58"/>
                    <measurement group_id="O2" value="2.2" spread="11.45"/>
                    <measurement group_id="O3" value="4.8" spread="13.28"/>
                    <measurement group_id="O4" value="4.6" spread="14.77"/>
                    <measurement group_id="O5" value="6.0" spread="13.79"/>
                    <measurement group_id="O6" value="6.2" spread="16.75"/>
                    <measurement group_id="O7" value="9.1" spread="17.21"/>
                    <measurement group_id="O8" value="2.0" spread="22.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Clinical Chemistry- Sodium, Potassium, Chloride and Bicarbonate Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit</title>
        <time_frame>Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)</time_frame>
        <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure and &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream Once Daily (QD)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 0.1% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 0.3% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 1.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 3.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Cream Twice Daily (BID)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 0.3% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841 1.0% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Clinical Chemistry- Sodium, Potassium, Chloride and Bicarbonate Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit</title>
          <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure and &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
          <units>Milliequivalents per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="35"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sodium: change at week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="34"/>
                    <count group_id="O7" value="36"/>
                    <count group_id="O8" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="2.34"/>
                    <measurement group_id="O2" value="-0.0" spread="1.77"/>
                    <measurement group_id="O3" value="-0.7" spread="2.04"/>
                    <measurement group_id="O4" value="-0.6" spread="2.17"/>
                    <measurement group_id="O5" value="-0.4" spread="3.50"/>
                    <measurement group_id="O6" value="0.4" spread="1.97"/>
                    <measurement group_id="O7" value="0.0" spread="2.08"/>
                    <measurement group_id="O8" value="-0.1" spread="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="2.23"/>
                    <measurement group_id="O2" value="-0.3" spread="1.89"/>
                    <measurement group_id="O3" value="-0.1" spread="2.39"/>
                    <measurement group_id="O4" value="-0.2" spread="2.18"/>
                    <measurement group_id="O5" value="-0.4" spread="3.61"/>
                    <measurement group_id="O6" value="-0.2" spread="2.61"/>
                    <measurement group_id="O7" value="-0.5" spread="2.20"/>
                    <measurement group_id="O8" value="-0.3" spread="3.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium:change at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="2.70"/>
                    <measurement group_id="O2" value="0.6" spread="1.83"/>
                    <measurement group_id="O3" value="-0.2" spread="2.44"/>
                    <measurement group_id="O4" value="-0.7" spread="2.71"/>
                    <measurement group_id="O5" value="-0.4" spread="3.08"/>
                    <measurement group_id="O6" value="-0.4" spread="2.72"/>
                    <measurement group_id="O7" value="-0.1" spread="1.77"/>
                    <measurement group_id="O8" value="-0.3" spread="3.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium:change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="2.31"/>
                    <measurement group_id="O2" value="0.0" spread="2.39"/>
                    <measurement group_id="O3" value="-0.2" spread="2.23"/>
                    <measurement group_id="O4" value="-0.9" spread="2.40"/>
                    <measurement group_id="O5" value="-0.9" spread="3.55"/>
                    <measurement group_id="O6" value="0.9" spread="2.50"/>
                    <measurement group_id="O7" value="-0.1" spread="2.23"/>
                    <measurement group_id="O8" value="-0.5" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium: change at follow up</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="31"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="3.26"/>
                    <measurement group_id="O2" value="0.5" spread="2.50"/>
                    <measurement group_id="O3" value="-0.1" spread="2.45"/>
                    <measurement group_id="O4" value="-0.3" spread="2.41"/>
                    <measurement group_id="O5" value="-0.8" spread="3.59"/>
                    <measurement group_id="O6" value="0.7" spread="1.94"/>
                    <measurement group_id="O7" value="-0.1" spread="2.46"/>
                    <measurement group_id="O8" value="0.1" spread="3.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium: change at week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="34"/>
                    <count group_id="O7" value="36"/>
                    <count group_id="O8" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00" spread="0.363"/>
                    <measurement group_id="O2" value="0.08" spread="0.282"/>
                    <measurement group_id="O3" value="0.03" spread="0.372"/>
                    <measurement group_id="O4" value="0.02" spread="0.347"/>
                    <measurement group_id="O5" value="0.07" spread="0.343"/>
                    <measurement group_id="O6" value="0.01" spread="0.337"/>
                    <measurement group_id="O7" value="0.00" spread="0.429"/>
                    <measurement group_id="O8" value="0.20" spread="0.464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium:change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.367"/>
                    <measurement group_id="O2" value="0.04" spread="0.298"/>
                    <measurement group_id="O3" value="-0.07" spread="0.338"/>
                    <measurement group_id="O4" value="0.04" spread="0.359"/>
                    <measurement group_id="O5" value="0.07" spread="0.346"/>
                    <measurement group_id="O6" value="0.00" spread="0.245"/>
                    <measurement group_id="O7" value="-0.16" spread="0.438"/>
                    <measurement group_id="O8" value="-0.02" spread="0.322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium: change at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.389"/>
                    <measurement group_id="O2" value="-0.06" spread="0.285"/>
                    <measurement group_id="O3" value="-0.02" spread="0.350"/>
                    <measurement group_id="O4" value="-0.01" spread="0.327"/>
                    <measurement group_id="O5" value="0.05" spread="0.375"/>
                    <measurement group_id="O6" value="-0.09" spread="0.300"/>
                    <measurement group_id="O7" value="-0.03" spread="0.415"/>
                    <measurement group_id="O8" value="0.26" spread="0.350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.373"/>
                    <measurement group_id="O2" value="0.03" spread="0.295"/>
                    <measurement group_id="O3" value="-0.06" spread="0.332"/>
                    <measurement group_id="O4" value="0.03" spread="0.407"/>
                    <measurement group_id="O5" value="-0.06" spread="0.262"/>
                    <measurement group_id="O6" value="-0.06" spread="0.309"/>
                    <measurement group_id="O7" value="-0.10" spread="0.355"/>
                    <measurement group_id="O8" value="0.09" spread="0.388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium: change at follow-up visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="31"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.379"/>
                    <measurement group_id="O2" value="0.10" spread="0.375"/>
                    <measurement group_id="O3" value="0.03" spread="0.394"/>
                    <measurement group_id="O4" value="0.04" spread="0.351"/>
                    <measurement group_id="O5" value="0.12" spread="0.358"/>
                    <measurement group_id="O6" value="0.05" spread="0.293"/>
                    <measurement group_id="O7" value="-0.09" spread="0.475"/>
                    <measurement group_id="O8" value="0.26" spread="0.460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride: change at week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="35"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="34"/>
                    <count group_id="O7" value="36"/>
                    <count group_id="O8" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="2.11"/>
                    <measurement group_id="O2" value="0.3" spread="1.86"/>
                    <measurement group_id="O3" value="0.3" spread="1.57"/>
                    <measurement group_id="O4" value="0.0" spread="2.54"/>
                    <measurement group_id="O5" value="0.0" spread="2.66"/>
                    <measurement group_id="O6" value="0.6" spread="2.11"/>
                    <measurement group_id="O7" value="0.5" spread="2.02"/>
                    <measurement group_id="O8" value="0.5" spread="2.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="2.52"/>
                    <measurement group_id="O2" value="-0.2" spread="2.08"/>
                    <measurement group_id="O3" value="0.7" spread="2.03"/>
                    <measurement group_id="O4" value="0.2" spread="2.50"/>
                    <measurement group_id="O5" value="-0.2" spread="2.87"/>
                    <measurement group_id="O6" value="0.4" spread="2.70"/>
                    <measurement group_id="O7" value="0.4" spread="2.15"/>
                    <measurement group_id="O8" value="0.2" spread="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride: change at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="2.05"/>
                    <measurement group_id="O2" value="0.6" spread="1.89"/>
                    <measurement group_id="O3" value="0.2" spread="2.68"/>
                    <measurement group_id="O4" value="-0.4" spread="2.23"/>
                    <measurement group_id="O5" value="-0.3" spread="2.16"/>
                    <measurement group_id="O6" value="0.3" spread="3.28"/>
                    <measurement group_id="O7" value="1.0" spread="2.21"/>
                    <measurement group_id="O8" value="-0.2" spread="2.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride:change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="1.98"/>
                    <measurement group_id="O2" value="0.1" spread="2.27"/>
                    <measurement group_id="O3" value="0.0" spread="2.34"/>
                    <measurement group_id="O4" value="-0.5" spread="2.44"/>
                    <measurement group_id="O5" value="-0.4" spread="3.05"/>
                    <measurement group_id="O6" value="0.5" spread="2.93"/>
                    <measurement group_id="O7" value="0.9" spread="2.73"/>
                    <measurement group_id="O8" value="0.0" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride: change at follow-up visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="31"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="2.97"/>
                    <measurement group_id="O2" value="-0.3" spread="2.16"/>
                    <measurement group_id="O3" value="0.8" spread="2.64"/>
                    <measurement group_id="O4" value="0.1" spread="2.41"/>
                    <measurement group_id="O5" value="-0.4" spread="2.90"/>
                    <measurement group_id="O6" value="1.3" spread="2.11"/>
                    <measurement group_id="O7" value="0.3" spread="2.35"/>
                    <measurement group_id="O8" value="0.4" spread="3.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate: change at week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                    <count group_id="O7" value="36"/>
                    <count group_id="O8" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="2.548"/>
                    <measurement group_id="O2" value="-0.38" spread="1.759"/>
                    <measurement group_id="O3" value="-0.20" spread="1.965"/>
                    <measurement group_id="O4" value="-0.18" spread="1.768"/>
                    <measurement group_id="O5" value="0.28" spread="1.638"/>
                    <measurement group_id="O6" value="0.09" spread="2.209"/>
                    <measurement group_id="O7" value="-0.21" spread="2.388"/>
                    <measurement group_id="O8" value="-0.02" spread="1.651"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="2.229"/>
                    <measurement group_id="O2" value="-0.40" spread="2.151"/>
                    <measurement group_id="O3" value="-0.51" spread="1.956"/>
                    <measurement group_id="O4" value="0.10" spread="2.129"/>
                    <measurement group_id="O5" value="-0.13" spread="1.931"/>
                    <measurement group_id="O6" value="-0.15" spread="2.341"/>
                    <measurement group_id="O7" value="-0.60" spread="2.354"/>
                    <measurement group_id="O8" value="-0.07" spread="1.828"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate: change at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="2.739"/>
                    <measurement group_id="O2" value="0.05" spread="2.128"/>
                    <measurement group_id="O3" value="-0.24" spread="2.484"/>
                    <measurement group_id="O4" value="0.34" spread="1.868"/>
                    <measurement group_id="O5" value="0.02" spread="2.011"/>
                    <measurement group_id="O6" value="0.14" spread="1.286"/>
                    <measurement group_id="O7" value="-0.00" spread="2.695"/>
                    <measurement group_id="O8" value="0.02" spread="1.704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="2.560"/>
                    <measurement group_id="O2" value="-0.44" spread="2.598"/>
                    <measurement group_id="O3" value="0.66" spread="2.132"/>
                    <measurement group_id="O4" value="0.27" spread="2.204"/>
                    <measurement group_id="O5" value="0.12" spread="2.407"/>
                    <measurement group_id="O6" value="0.63" spread="2.096"/>
                    <measurement group_id="O7" value="-0.19" spread="2.038"/>
                    <measurement group_id="O8" value="-0.20" spread="2.217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate: change at follow-up visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="31"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="2.916"/>
                    <measurement group_id="O2" value="0.66" spread="2.209"/>
                    <measurement group_id="O3" value="0.41" spread="2.056"/>
                    <measurement group_id="O4" value="0.75" spread="2.386"/>
                    <measurement group_id="O5" value="0.43" spread="2.162"/>
                    <measurement group_id="O6" value="0.08" spread="1.643"/>
                    <measurement group_id="O7" value="0.18" spread="2.300"/>
                    <measurement group_id="O8" value="1.09" spread="2.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology- Hemoglobin Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit</title>
        <time_frame>Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)</time_frame>
        <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure and &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream Once Daily (QD)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 0.1% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 0.3% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 1.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 3.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Cream Twice Daily (BID)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 0.3% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841 1.0% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology- Hemoglobin Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit</title>
          <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure and &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
          <units>Gram per deciliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="35"/>
                <count group_id="O8" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.790"/>
                    <measurement group_id="O2" value="-0.22" spread="0.620"/>
                    <measurement group_id="O3" value="-0.36" spread="0.775"/>
                    <measurement group_id="O4" value="-0.12" spread="0.678"/>
                    <measurement group_id="O5" value="-0.26" spread="0.726"/>
                    <measurement group_id="O6" value="-0.19" spread="0.698"/>
                    <measurement group_id="O7" value="-0.21" spread="0.584"/>
                    <measurement group_id="O8" value="-0.27" spread="0.679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.636"/>
                    <measurement group_id="O2" value="-0.09" spread="0.566"/>
                    <measurement group_id="O3" value="-0.64" spread="0.715"/>
                    <measurement group_id="O4" value="-0.24" spread="0.657"/>
                    <measurement group_id="O5" value="-0.22" spread="0.798"/>
                    <measurement group_id="O6" value="-0.16" spread="0.830"/>
                    <measurement group_id="O7" value="-0.25" spread="0.625"/>
                    <measurement group_id="O8" value="-0.32" spread="0.793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.725"/>
                    <measurement group_id="O2" value="-0.17" spread="0.630"/>
                    <measurement group_id="O3" value="-0.48" spread="0.659"/>
                    <measurement group_id="O4" value="-0.25" spread="0.628"/>
                    <measurement group_id="O5" value="-0.06" spread="0.821"/>
                    <measurement group_id="O6" value="-0.27" spread="0.789"/>
                    <measurement group_id="O7" value="-0.32" spread="0.701"/>
                    <measurement group_id="O8" value="-0.20" spread="0.658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.832"/>
                    <measurement group_id="O2" value="-0.06" spread="0.614"/>
                    <measurement group_id="O3" value="-0.48" spread="0.767"/>
                    <measurement group_id="O4" value="-0.03" spread="0.617"/>
                    <measurement group_id="O5" value="-0.11" spread="0.775"/>
                    <measurement group_id="O6" value="-0.22" spread="0.724"/>
                    <measurement group_id="O7" value="-0.21" spread="0.833"/>
                    <measurement group_id="O8" value="-0.28" spread="0.683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at follow-up visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="31"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.613"/>
                    <measurement group_id="O2" value="-0.04" spread="0.717"/>
                    <measurement group_id="O3" value="-0.49" spread="0.777"/>
                    <measurement group_id="O4" value="-0.09" spread="0.784"/>
                    <measurement group_id="O5" value="0.00" spread="0.773"/>
                    <measurement group_id="O6" value="-0.27" spread="0.756"/>
                    <measurement group_id="O7" value="-0.12" spread="0.826"/>
                    <measurement group_id="O8" value="-0.18" spread="0.740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology - Hematocrit, Reticulocytes/Erythrocytes, Lymphocytes/Leukocytes, Neutrophils/Leukocytes, Basophils/Leukocytes, Eosinophils/Leukocytes and Monocytes/Leukocytes Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit</title>
        <time_frame>Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)</time_frame>
        <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure and &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream Once Daily (QD)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 0.1% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 0.3% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 1.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 3.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Cream Twice Daily (BID)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 0.3% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841 1.0% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology - Hematocrit, Reticulocytes/Erythrocytes, Lymphocytes/Leukocytes, Neutrophils/Leukocytes, Basophils/Leukocytes, Eosinophils/Leukocytes and Monocytes/Leukocytes Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit</title>
          <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure and &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
          <units>Percentage of cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="35"/>
                <count group_id="O8" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit: change at week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="2.51"/>
                    <measurement group_id="O2" value="-0.8" spread="2.11"/>
                    <measurement group_id="O3" value="-1.3" spread="2.61"/>
                    <measurement group_id="O4" value="-0.4" spread="2.27"/>
                    <measurement group_id="O5" value="-0.8" spread="2.41"/>
                    <measurement group_id="O6" value="-0.5" spread="1.97"/>
                    <measurement group_id="O7" value="-0.9" spread="2.04"/>
                    <measurement group_id="O8" value="-0.9" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="2.19"/>
                    <measurement group_id="O2" value="-0.8" spread="2.12"/>
                    <measurement group_id="O3" value="-1.8" spread="2.42"/>
                    <measurement group_id="O4" value="-0.9" spread="2.32"/>
                    <measurement group_id="O5" value="-0.7" spread="2.58"/>
                    <measurement group_id="O6" value="-0.9" spread="2.55"/>
                    <measurement group_id="O7" value="-0.7" spread="2.24"/>
                    <measurement group_id="O8" value="-1.0" spread="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit: change at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="30"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="2.45"/>
                    <measurement group_id="O2" value="-0.8" spread="1.96"/>
                    <measurement group_id="O3" value="-1.8" spread="2.06"/>
                    <measurement group_id="O4" value="-0.8" spread="2.34"/>
                    <measurement group_id="O5" value="0.0" spread="2.73"/>
                    <measurement group_id="O6" value="-1.0" spread="2.34"/>
                    <measurement group_id="O7" value="-0.9" spread="2.29"/>
                    <measurement group_id="O8" value="-0.5" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="2.47"/>
                    <measurement group_id="O2" value="-0.9" spread="1.93"/>
                    <measurement group_id="O3" value="-1.6" spread="2.64"/>
                    <measurement group_id="O4" value="-0.7" spread="2.23"/>
                    <measurement group_id="O5" value="-0.6" spread="2.51"/>
                    <measurement group_id="O6" value="-1.1" spread="1.98"/>
                    <measurement group_id="O7" value="-1.1" spread="2.84"/>
                    <measurement group_id="O8" value="-0.8" spread="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit: change at follow-up (FU) visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="31"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="2.49"/>
                    <measurement group_id="O2" value="-0.7" spread="2.24"/>
                    <measurement group_id="O3" value="-1.4" spread="3.05"/>
                    <measurement group_id="O4" value="-0.7" spread="2.39"/>
                    <measurement group_id="O5" value="-0.2" spread="2.50"/>
                    <measurement group_id="O6" value="-0.6" spread="2.20"/>
                    <measurement group_id="O7" value="-0.6" spread="2.73"/>
                    <measurement group_id="O8" value="-0.3" spread="2.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes/Erythrocytes change at week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="29"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="28"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.317"/>
                    <measurement group_id="O2" value="0.14" spread="0.378"/>
                    <measurement group_id="O3" value="0.02" spread="0.483"/>
                    <measurement group_id="O4" value="0.06" spread="0.364"/>
                    <measurement group_id="O5" value="0.11" spread="0.318"/>
                    <measurement group_id="O6" value="0.01" spread="0.320"/>
                    <measurement group_id="O7" value="0.04" spread="0.355"/>
                    <measurement group_id="O8" value="0.01" spread="0.329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes/Erythrocytes: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="29"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="26"/>
                    <count group_id="O7" value="29"/>
                    <count group_id="O8" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.382"/>
                    <measurement group_id="O2" value="0.17" spread="0.325"/>
                    <measurement group_id="O3" value="0.09" spread="0.413"/>
                    <measurement group_id="O4" value="-0.02" spread="0.473"/>
                    <measurement group_id="O5" value="0.19" spread="0.443"/>
                    <measurement group_id="O6" value="-0.10" spread="0.318"/>
                    <measurement group_id="O7" value="0.06" spread="0.315"/>
                    <measurement group_id="O8" value="-0.01" spread="0.389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes/Erythrocytes: change at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="26"/>
                    <count group_id="O8" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.596"/>
                    <measurement group_id="O2" value="-0.08" spread="0.359"/>
                    <measurement group_id="O3" value="0.01" spread="0.460"/>
                    <measurement group_id="O4" value="0.19" spread="0.429"/>
                    <measurement group_id="O5" value="0.10" spread="0.409"/>
                    <measurement group_id="O6" value="0.03" spread="0.290"/>
                    <measurement group_id="O7" value="0.04" spread="0.446"/>
                    <measurement group_id="O8" value="0.05" spread="0.374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes/Erythrocytes: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="28"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="22"/>
                    <count group_id="O7" value="28"/>
                    <count group_id="O8" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.382"/>
                    <measurement group_id="O2" value="0.02" spread="0.361"/>
                    <measurement group_id="O3" value="0.02" spread="0.473"/>
                    <measurement group_id="O4" value="0.01" spread="0.486"/>
                    <measurement group_id="O5" value="0.15" spread="0.399"/>
                    <measurement group_id="O6" value="-0.15" spread="0.310"/>
                    <measurement group_id="O7" value="-0.01" spread="0.355"/>
                    <measurement group_id="O8" value="0.01" spread="0.463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes/Erythrocytes:change at FU visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="27"/>
                    <count group_id="O7" value="27"/>
                    <count group_id="O8" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.396"/>
                    <measurement group_id="O2" value="-0.02" spread="0.384"/>
                    <measurement group_id="O3" value="0.10" spread="0.435"/>
                    <measurement group_id="O4" value="-0.10" spread="0.398"/>
                    <measurement group_id="O5" value="-0.03" spread="0.298"/>
                    <measurement group_id="O6" value="-0.09" spread="0.331"/>
                    <measurement group_id="O7" value="-0.19" spread="0.395"/>
                    <measurement group_id="O8" value="0.11" spread="0.448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes/Leukocytes: change at week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="6.772"/>
                    <measurement group_id="O2" value="0.68" spread="5.814"/>
                    <measurement group_id="O3" value="2.33" spread="5.616"/>
                    <measurement group_id="O4" value="0.06" spread="4.765"/>
                    <measurement group_id="O5" value="1.31" spread="6.259"/>
                    <measurement group_id="O6" value="0.59" spread="5.179"/>
                    <measurement group_id="O7" value="0.49" spread="5.509"/>
                    <measurement group_id="O8" value="1.79" spread="6.269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes/Leukocytes: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="6.175"/>
                    <measurement group_id="O2" value="0.84" spread="7.544"/>
                    <measurement group_id="O3" value="1.68" spread="5.208"/>
                    <measurement group_id="O4" value="1.50" spread="5.639"/>
                    <measurement group_id="O5" value="0.23" spread="6.175"/>
                    <measurement group_id="O6" value="0.50" spread="5.405"/>
                    <measurement group_id="O7" value="0.72" spread="6.638"/>
                    <measurement group_id="O8" value="0.86" spread="7.264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes/Leukocytes: change at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" spread="7.591"/>
                    <measurement group_id="O2" value="0.51" spread="7.297"/>
                    <measurement group_id="O3" value="1.43" spread="5.298"/>
                    <measurement group_id="O4" value="0.43" spread="7.586"/>
                    <measurement group_id="O5" value="2.41" spread="6.577"/>
                    <measurement group_id="O6" value="-1.38" spread="5.415"/>
                    <measurement group_id="O7" value="1.07" spread="5.739"/>
                    <measurement group_id="O8" value="0.56" spread="7.264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes/Leukocytes: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" spread="6.701"/>
                    <measurement group_id="O2" value="-0.06" spread="5.461"/>
                    <measurement group_id="O3" value="0.82" spread="6.685"/>
                    <measurement group_id="O4" value="1.28" spread="5.881"/>
                    <measurement group_id="O5" value="1.65" spread="5.818"/>
                    <measurement group_id="O6" value="0.50" spread="4.452"/>
                    <measurement group_id="O7" value="-0.04" spread="5.300"/>
                    <measurement group_id="O8" value="1.52" spread="7.266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes/Leukocytes: change at follow-up visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="31"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="6.219"/>
                    <measurement group_id="O2" value="1.25" spread="4.974"/>
                    <measurement group_id="O3" value="1.61" spread="6.597"/>
                    <measurement group_id="O4" value="-0.85" spread="6.367"/>
                    <measurement group_id="O5" value="1.34" spread="6.165"/>
                    <measurement group_id="O6" value="0.22" spread="6.315"/>
                    <measurement group_id="O7" value="0.07" spread="5.103"/>
                    <measurement group_id="O8" value="2.48" spread="6.914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils/Leukocytes: change at week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" spread="7.515"/>
                    <measurement group_id="O2" value="-0.95" spread="6.957"/>
                    <measurement group_id="O3" value="-2.93" spread="6.191"/>
                    <measurement group_id="O4" value="0.30" spread="5.755"/>
                    <measurement group_id="O5" value="-0.96" spread="7.843"/>
                    <measurement group_id="O6" value="-0.17" spread="5.769"/>
                    <measurement group_id="O7" value="-1.87" spread="6.873"/>
                    <measurement group_id="O8" value="-1.44" spread="6.580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils/Leukocytes: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="7.827"/>
                    <measurement group_id="O2" value="-0.34" spread="8.219"/>
                    <measurement group_id="O3" value="-1.70" spread="6.037"/>
                    <measurement group_id="O4" value="-1.50" spread="6.578"/>
                    <measurement group_id="O5" value="-0.24" spread="6.146"/>
                    <measurement group_id="O6" value="-0.49" spread="6.665"/>
                    <measurement group_id="O7" value="-1.04" spread="7.376"/>
                    <measurement group_id="O8" value="-0.56" spread="8.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils/Leukocytes: change at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.42" spread="8.812"/>
                    <measurement group_id="O2" value="-0.30" spread="7.754"/>
                    <measurement group_id="O3" value="-1.52" spread="6.661"/>
                    <measurement group_id="O4" value="0.06" spread="8.536"/>
                    <measurement group_id="O5" value="-2.25" spread="7.468"/>
                    <measurement group_id="O6" value="1.65" spread="6.622"/>
                    <measurement group_id="O7" value="-1.42" spread="6.498"/>
                    <measurement group_id="O8" value="-0.45" spread="7.362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils/Leukocytes: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" spread="8.648"/>
                    <measurement group_id="O2" value="-0.58" spread="7.009"/>
                    <measurement group_id="O3" value="-0.64" spread="6.833"/>
                    <measurement group_id="O4" value="-1.14" spread="6.872"/>
                    <measurement group_id="O5" value="-1.15" spread="6.969"/>
                    <measurement group_id="O6" value="-0.56" spread="5.699"/>
                    <measurement group_id="O7" value="0.13" spread="6.029"/>
                    <measurement group_id="O8" value="-1.01" spread="8.445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils/Leukocytes: change at follow-up visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="31"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.71" spread="7.046"/>
                    <measurement group_id="O2" value="-0.65" spread="6.057"/>
                    <measurement group_id="O3" value="-1.86" spread="6.892"/>
                    <measurement group_id="O4" value="1.32" spread="7.355"/>
                    <measurement group_id="O5" value="-1.32" spread="6.559"/>
                    <measurement group_id="O6" value="-0.41" spread="6.961"/>
                    <measurement group_id="O7" value="-0.71" spread="6.590"/>
                    <measurement group_id="O8" value="-2.04" spread="7.700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils/Leukocytes: change at week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.431"/>
                    <measurement group_id="O2" value="-0.02" spread="0.690"/>
                    <measurement group_id="O3" value="-0.06" spread="0.524"/>
                    <measurement group_id="O4" value="0.08" spread="0.319"/>
                    <measurement group_id="O5" value="0.03" spread="0.515"/>
                    <measurement group_id="O6" value="-0.03" spread="0.291"/>
                    <measurement group_id="O7" value="-0.01" spread="0.411"/>
                    <measurement group_id="O8" value="-0.01" spread="0.570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils/Leukocytes: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.304"/>
                    <measurement group_id="O2" value="0.01" spread="0.493"/>
                    <measurement group_id="O3" value="-0.09" spread="0.342"/>
                    <measurement group_id="O4" value="0.02" spread="0.323"/>
                    <measurement group_id="O5" value="-0.03" spread="0.532"/>
                    <measurement group_id="O6" value="0.03" spread="0.355"/>
                    <measurement group_id="O7" value="-0.06" spread="0.624"/>
                    <measurement group_id="O8" value="-0.24" spread="0.709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils/Leukocytes: change at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.485"/>
                    <measurement group_id="O2" value="0.06" spread="0.651"/>
                    <measurement group_id="O3" value="-0.03" spread="0.420"/>
                    <measurement group_id="O4" value="0.01" spread="0.402"/>
                    <measurement group_id="O5" value="-0.08" spread="0.712"/>
                    <measurement group_id="O6" value="-0.05" spread="0.362"/>
                    <measurement group_id="O7" value="-0.01" spread="0.465"/>
                    <measurement group_id="O8" value="-0.10" spread="0.464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils/Leukocytes: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.272"/>
                    <measurement group_id="O2" value="0.11" spread="0.809"/>
                    <measurement group_id="O3" value="-0.12" spread="0.480"/>
                    <measurement group_id="O4" value="0.08" spread="0.458"/>
                    <measurement group_id="O5" value="-0.16" spread="0.557"/>
                    <measurement group_id="O6" value="-0.05" spread="0.296"/>
                    <measurement group_id="O7" value="-0.12" spread="0.576"/>
                    <measurement group_id="O8" value="-0.17" spread="0.750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils/Leukocytes: change at follow-up visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="31"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.360"/>
                    <measurement group_id="O2" value="-0.15" spread="0.476"/>
                    <measurement group_id="O3" value="-0.13" spread="0.443"/>
                    <measurement group_id="O4" value="0.02" spread="0.512"/>
                    <measurement group_id="O5" value="-0.25" spread="0.541"/>
                    <measurement group_id="O6" value="-0.05" spread="0.449"/>
                    <measurement group_id="O7" value="0.01" spread="0.472"/>
                    <measurement group_id="O8" value="-0.25" spread="0.572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils/Leukocytes: change at week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="1.390"/>
                    <measurement group_id="O2" value="0.17" spread="1.840"/>
                    <measurement group_id="O3" value="0.17" spread="0.934"/>
                    <measurement group_id="O4" value="-0.37" spread="1.549"/>
                    <measurement group_id="O5" value="-0.31" spread="1.607"/>
                    <measurement group_id="O6" value="-0.19" spread="1.410"/>
                    <measurement group_id="O7" value="0.89" spread="1.850"/>
                    <measurement group_id="O8" value="-0.23" spread="1.339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils/Leukocytes: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="1.801"/>
                    <measurement group_id="O2" value="-0.20" spread="1.298"/>
                    <measurement group_id="O3" value="-0.16" spread="1.284"/>
                    <measurement group_id="O4" value="0.11" spread="1.460"/>
                    <measurement group_id="O5" value="-0.27" spread="1.131"/>
                    <measurement group_id="O6" value="-0.14" spread="1.199"/>
                    <measurement group_id="O7" value="0.16" spread="1.304"/>
                    <measurement group_id="O8" value="-0.05" spread="1.531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils/Leukocytes: change at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="1.982"/>
                    <measurement group_id="O2" value="-0.12" spread="1.725"/>
                    <measurement group_id="O3" value="0.15" spread="1.884"/>
                    <measurement group_id="O4" value="-0.37" spread="1.729"/>
                    <measurement group_id="O5" value="-0.35" spread="1.431"/>
                    <measurement group_id="O6" value="-0.34" spread="1.258"/>
                    <measurement group_id="O7" value="0.40" spread="1.468"/>
                    <measurement group_id="O8" value="-0.37" spread="1.747"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils/Leukocytes: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="1.522"/>
                    <measurement group_id="O2" value="0.22" spread="1.570"/>
                    <measurement group_id="O3" value="-0.04" spread="1.213"/>
                    <measurement group_id="O4" value="0.02" spread="2.126"/>
                    <measurement group_id="O5" value="-0.15" spread="1.714"/>
                    <measurement group_id="O6" value="-0.01" spread="1.767"/>
                    <measurement group_id="O7" value="0.05" spread="1.229"/>
                    <measurement group_id="O8" value="-0.19" spread="1.840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils/Leukocytes: change at follow-up visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="31"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="1.754"/>
                    <measurement group_id="O2" value="-0.24" spread="1.860"/>
                    <measurement group_id="O3" value="-0.09" spread="1.155"/>
                    <measurement group_id="O4" value="-0.41" spread="2.188"/>
                    <measurement group_id="O5" value="0.12" spread="1.954"/>
                    <measurement group_id="O6" value="-0.05" spread="2.805"/>
                    <measurement group_id="O7" value="0.50" spread="1.986"/>
                    <measurement group_id="O8" value="-0.13" spread="2.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes/Leukocytes: change at week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="1.913"/>
                    <measurement group_id="O2" value="0.12" spread="1.391"/>
                    <measurement group_id="O3" value="0.50" spread="1.428"/>
                    <measurement group_id="O4" value="-0.06" spread="1.409"/>
                    <measurement group_id="O5" value="-0.01" spread="1.593"/>
                    <measurement group_id="O6" value="-0.19" spread="1.043"/>
                    <measurement group_id="O7" value="0.51" spread="1.275"/>
                    <measurement group_id="O8" value="-0.11" spread="1.251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes/Leukocytes: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="2.055"/>
                    <measurement group_id="O2" value="-0.31" spread="1.502"/>
                    <measurement group_id="O3" value="0.30" spread="1.522"/>
                    <measurement group_id="O4" value="-0.13" spread="1.267"/>
                    <measurement group_id="O5" value="0.38" spread="1.362"/>
                    <measurement group_id="O6" value="0.11" spread="1.318"/>
                    <measurement group_id="O7" value="0.22" spread="1.414"/>
                    <measurement group_id="O8" value="-0.01" spread="1.755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes/Leukocytes : change at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="2.509"/>
                    <measurement group_id="O2" value="-0.17" spread="1.966"/>
                    <measurement group_id="O3" value="-0.02" spread="2.072"/>
                    <measurement group_id="O4" value="-0.10" spread="1.582"/>
                    <measurement group_id="O5" value="0.22" spread="1.323"/>
                    <measurement group_id="O6" value="0.14" spread="1.323"/>
                    <measurement group_id="O7" value="-0.03" spread="1.039"/>
                    <measurement group_id="O8" value="0.33" spread="1.695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes/Leukocytes : change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="2.488"/>
                    <measurement group_id="O2" value="0.33" spread="2.257"/>
                    <measurement group_id="O3" value="-0.00" spread="1.813"/>
                    <measurement group_id="O4" value="-0.24" spread="1.217"/>
                    <measurement group_id="O5" value="-0.12" spread="1.030"/>
                    <measurement group_id="O6" value="0.13" spread="0.807"/>
                    <measurement group_id="O7" value="-0.02" spread="1.324"/>
                    <measurement group_id="O8" value="-0.16" spread="1.516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes/Leukocytes : change at follow-up visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="31"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="2.105"/>
                    <measurement group_id="O2" value="-0.22" spread="1.304"/>
                    <measurement group_id="O3" value="0.50" spread="1.463"/>
                    <measurement group_id="O4" value="-0.07" spread="1.226"/>
                    <measurement group_id="O5" value="0.13" spread="1.205"/>
                    <measurement group_id="O6" value="0.26" spread="1.543"/>
                    <measurement group_id="O7" value="0.15" spread="1.599"/>
                    <measurement group_id="O8" value="-0.04" spread="1.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology- Erythrocytes and Reticulocytes Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit</title>
        <time_frame>Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)</time_frame>
        <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure and &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream Once Daily (QD)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 0.1% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 0.3% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 1.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 3.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Cream Twice Daily (BID)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 0.3% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841 1.0% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology- Erythrocytes and Reticulocytes Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit</title>
          <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure and &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
          <units>10^12*cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="35"/>
                <count group_id="O8" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythrocytes: change at week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.261"/>
                    <measurement group_id="O2" value="-0.07" spread="0.232"/>
                    <measurement group_id="O3" value="-0.12" spread="0.264"/>
                    <measurement group_id="O4" value="-0.04" spread="0.252"/>
                    <measurement group_id="O5" value="-0.08" spread="0.254"/>
                    <measurement group_id="O6" value="-0.08" spread="0.298"/>
                    <measurement group_id="O7" value="-0.08" spread="0.192"/>
                    <measurement group_id="O8" value="-0.09" spread="0.240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocytes: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.234"/>
                    <measurement group_id="O2" value="-0.03" spread="0.212"/>
                    <measurement group_id="O3" value="-0.18" spread="0.251"/>
                    <measurement group_id="O4" value="-0.10" spread="0.208"/>
                    <measurement group_id="O5" value="-0.07" spread="0.242"/>
                    <measurement group_id="O6" value="-0.10" spread="0.366"/>
                    <measurement group_id="O7" value="-0.06" spread="0.229"/>
                    <measurement group_id="O8" value="-0.11" spread="0.232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocytes: change at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.216"/>
                    <measurement group_id="O2" value="-0.05" spread="0.221"/>
                    <measurement group_id="O3" value="-0.16" spread="0.251"/>
                    <measurement group_id="O4" value="-0.10" spread="0.233"/>
                    <measurement group_id="O5" value="0.01" spread="0.275"/>
                    <measurement group_id="O6" value="-0.12" spread="0.271"/>
                    <measurement group_id="O7" value="-0.08" spread="0.248"/>
                    <measurement group_id="O8" value="-0.06" spread="0.219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocytes: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.247"/>
                    <measurement group_id="O2" value="-0.01" spread="0.180"/>
                    <measurement group_id="O3" value="-0.17" spread="0.265"/>
                    <measurement group_id="O4" value="-0.04" spread="0.238"/>
                    <measurement group_id="O5" value="-0.02" spread="0.262"/>
                    <measurement group_id="O6" value="-0.10" spread="0.256"/>
                    <measurement group_id="O7" value="-0.07" spread="0.303"/>
                    <measurement group_id="O8" value="-0.08" spread="0.239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocytes: change at follow-up visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="31"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.220"/>
                    <measurement group_id="O2" value="0.02" spread="0.244"/>
                    <measurement group_id="O3" value="-0.15" spread="0.266"/>
                    <measurement group_id="O4" value="-0.03" spread="0.254"/>
                    <measurement group_id="O5" value="0.04" spread="0.300"/>
                    <measurement group_id="O6" value="-0.08" spread="0.280"/>
                    <measurement group_id="O7" value="-0.03" spread="0.308"/>
                    <measurement group_id="O8" value="-0.05" spread="0.262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes: change at week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="29"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="28"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.02"/>
                    <measurement group_id="O2" value="0.0" spread="0.02"/>
                    <measurement group_id="O3" value="-0.0" spread="0.02"/>
                    <measurement group_id="O4" value="0.0" spread="0.02"/>
                    <measurement group_id="O5" value="0.0" spread="0.02"/>
                    <measurement group_id="O6" value="0.0" spread="0.01"/>
                    <measurement group_id="O7" value="0.0" spread="0.02"/>
                    <measurement group_id="O8" value="-0.0" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="29"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="26"/>
                    <count group_id="O7" value="29"/>
                    <count group_id="O8" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" spread="0.02"/>
                    <measurement group_id="O2" value="0.0" spread="0.02"/>
                    <measurement group_id="O3" value="0.0" spread="0.02"/>
                    <measurement group_id="O4" value="-0.0" spread="0.02"/>
                    <measurement group_id="O5" value="0.0" spread="0.02"/>
                    <measurement group_id="O6" value="-0.0" spread="0.02"/>
                    <measurement group_id="O7" value="0.0" spread="0.02"/>
                    <measurement group_id="O8" value="-0.0" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes: change at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="25"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="26"/>
                    <count group_id="O8" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.03"/>
                    <measurement group_id="O2" value="-0.0" spread="0.02"/>
                    <measurement group_id="O3" value="-0.0" spread="0.02"/>
                    <measurement group_id="O4" value="0.0" spread="0.02"/>
                    <measurement group_id="O5" value="0.0" spread="0.02"/>
                    <measurement group_id="O6" value="-0.0" spread="0.01"/>
                    <measurement group_id="O7" value="-0.0" spread="0.02"/>
                    <measurement group_id="O8" value="0.0" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="28"/>
                    <count group_id="O4" value="28"/>
                    <count group_id="O5" value="24"/>
                    <count group_id="O6" value="22"/>
                    <count group_id="O7" value="28"/>
                    <count group_id="O8" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" spread="0.02"/>
                    <measurement group_id="O2" value="0.0" spread="0.02"/>
                    <measurement group_id="O3" value="0.0" spread="0.02"/>
                    <measurement group_id="O4" value="-0.0" spread="0.02"/>
                    <measurement group_id="O5" value="0.0" spread="0.02"/>
                    <measurement group_id="O6" value="-0.0" spread="0.01"/>
                    <measurement group_id="O7" value="-0.0" spread="0.02"/>
                    <measurement group_id="O8" value="0.0" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes: change at follow-up visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="27"/>
                    <count group_id="O4" value="27"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="27"/>
                    <count group_id="O7" value="27"/>
                    <count group_id="O8" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" spread="0.02"/>
                    <measurement group_id="O2" value="-0.0" spread="0.02"/>
                    <measurement group_id="O3" value="0.0" spread="0.02"/>
                    <measurement group_id="O4" value="-0.0" spread="0.02"/>
                    <measurement group_id="O5" value="-0.0" spread="0.01"/>
                    <measurement group_id="O6" value="-0.0" spread="0.02"/>
                    <measurement group_id="O7" value="-0.0" spread="0.02"/>
                    <measurement group_id="O8" value="0.0" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hematology- Platelets, Leukocytes, Lymphocytes, Neutrophils, Basophils, Eosinophils and Monocytes Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit</title>
        <time_frame>Baseline, Weeks 1, 2, 4, 6 and follow up visit (28 days after last dose of study drug = maximum up to Day 71)</time_frame>
        <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure and &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream Once Daily (QD)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 0.1% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 0.3% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 1.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 3.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Cream Twice Daily (BID)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 0.3% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841 1.0% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematology- Platelets, Leukocytes, Lymphocytes, Neutrophils, Basophils, Eosinophils and Monocytes Laboratory Values at Weeks 1, 2, 4, 6 and Follow-up Visit</title>
          <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure and &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
          <units>10^9 *cells per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="35"/>
                <count group_id="O8" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Platelets: change at week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="60.03"/>
                    <measurement group_id="O2" value="6.8" spread="34.08"/>
                    <measurement group_id="O3" value="-3.3" spread="32.39"/>
                    <measurement group_id="O4" value="1.0" spread="25.76"/>
                    <measurement group_id="O5" value="8.5" spread="41.61"/>
                    <measurement group_id="O6" value="6.6" spread="33.40"/>
                    <measurement group_id="O7" value="-2.1" spread="31.94"/>
                    <measurement group_id="O8" value="12.6" spread="44.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="58.16"/>
                    <measurement group_id="O2" value="7.1" spread="43.34"/>
                    <measurement group_id="O3" value="-8.1" spread="41.92"/>
                    <measurement group_id="O4" value="-0.1" spread="32.45"/>
                    <measurement group_id="O5" value="5.0" spread="31.39"/>
                    <measurement group_id="O6" value="-4.9" spread="31.84"/>
                    <measurement group_id="O7" value="7.5" spread="37.94"/>
                    <measurement group_id="O8" value="14.8" spread="50.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets: change at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="36.42"/>
                    <measurement group_id="O2" value="10.1" spread="37.55"/>
                    <measurement group_id="O3" value="-2.4" spread="37.68"/>
                    <measurement group_id="O4" value="-0.3" spread="36.27"/>
                    <measurement group_id="O5" value="-5.9" spread="37.47"/>
                    <measurement group_id="O6" value="4.4" spread="37.79"/>
                    <measurement group_id="O7" value="0.7" spread="36.51"/>
                    <measurement group_id="O8" value="11.0" spread="46.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="35.17"/>
                    <measurement group_id="O2" value="-3.3" spread="32.76"/>
                    <measurement group_id="O3" value="-6.6" spread="41.66"/>
                    <measurement group_id="O4" value="-2.3" spread="32.70"/>
                    <measurement group_id="O5" value="-5.2" spread="38.53"/>
                    <measurement group_id="O6" value="0.2" spread="37.28"/>
                    <measurement group_id="O7" value="-1.8" spread="37.05"/>
                    <measurement group_id="O8" value="8.6" spread="47.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets: change at follow-up visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="31"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="30.48"/>
                    <measurement group_id="O2" value="16.3" spread="37.13"/>
                    <measurement group_id="O3" value="-8.5" spread="30.15"/>
                    <measurement group_id="O4" value="0.1" spread="32.36"/>
                    <measurement group_id="O5" value="10.2" spread="47.30"/>
                    <measurement group_id="O6" value="-5.2" spread="40.70"/>
                    <measurement group_id="O7" value="5.8" spread="48.55"/>
                    <measurement group_id="O8" value="2.5" spread="58.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes: change at week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.027" spread="1.8740"/>
                    <measurement group_id="O2" value="0.395" spread="1.0940"/>
                    <measurement group_id="O3" value="-0.051" spread="1.2403"/>
                    <measurement group_id="O4" value="0.407" spread="1.2225"/>
                    <measurement group_id="O5" value="0.259" spread="1.1290"/>
                    <measurement group_id="O6" value="0.068" spread="1.2929"/>
                    <measurement group_id="O7" value="0.238" spread="1.4993"/>
                    <measurement group_id="O8" value="-0.025" spread="2.3529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.206" spread="1.8886"/>
                    <measurement group_id="O2" value="0.459" spread="1.5567"/>
                    <measurement group_id="O3" value="-0.288" spread="1.6842"/>
                    <measurement group_id="O4" value="-0.094" spread="1.2877"/>
                    <measurement group_id="O5" value="-0.116" spread="1.0364"/>
                    <measurement group_id="O6" value="-0.007" spread="1.2637"/>
                    <measurement group_id="O7" value="0.422" spread="1.8986"/>
                    <measurement group_id="O8" value="-0.006" spread="2.3428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes: change at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.203" spread="1.7390"/>
                    <measurement group_id="O2" value="0.729" spread="1.3199"/>
                    <measurement group_id="O3" value="0.189" spread="1.3534"/>
                    <measurement group_id="O4" value="0.085" spread="1.3541"/>
                    <measurement group_id="O5" value="-0.074" spread="1.0641"/>
                    <measurement group_id="O6" value="0.398" spread="1.5999"/>
                    <measurement group_id="O7" value="0.168" spread="1.0902"/>
                    <measurement group_id="O8" value="0.041" spread="2.1647"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.160" spread="1.7059"/>
                    <measurement group_id="O2" value="0.066" spread="1.0672"/>
                    <measurement group_id="O3" value="-0.505" spread="1.6474"/>
                    <measurement group_id="O4" value="0.237" spread="1.4501"/>
                    <measurement group_id="O5" value="-0.244" spread="1.2763"/>
                    <measurement group_id="O6" value="-0.269" spread="1.0761"/>
                    <measurement group_id="O7" value="-0.048" spread="1.3823"/>
                    <measurement group_id="O8" value="-0.347" spread="2.1442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes: change at follow-up visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="31"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.066" spread="1.5744"/>
                    <measurement group_id="O2" value="0.479" spread="1.0939"/>
                    <measurement group_id="O3" value="-0.048" spread="2.0206"/>
                    <measurement group_id="O4" value="0.329" spread="1.3938"/>
                    <measurement group_id="O5" value="0.123" spread="0.8496"/>
                    <measurement group_id="O6" value="-0.117" spread="1.4856"/>
                    <measurement group_id="O7" value="0.210" spread="1.7456"/>
                    <measurement group_id="O8" value="-0.404" spread="2.4817"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes: change at week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.008" spread="0.5539"/>
                    <measurement group_id="O2" value="0.124" spread="0.3659"/>
                    <measurement group_id="O3" value="0.107" spread="0.3130"/>
                    <measurement group_id="O4" value="0.081" spread="0.3839"/>
                    <measurement group_id="O5" value="0.186" spread="0.3840"/>
                    <measurement group_id="O6" value="0.051" spread="0.3557"/>
                    <measurement group_id="O7" value="0.089" spread="0.4320"/>
                    <measurement group_id="O8" value="0.223" spread="0.3849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.061" spread="0.5558"/>
                    <measurement group_id="O2" value="0.145" spread="0.3735"/>
                    <measurement group_id="O3" value="0.010" spread="0.4115"/>
                    <measurement group_id="O4" value="0.044" spread="0.4225"/>
                    <measurement group_id="O5" value="0.012" spread="0.4251"/>
                    <measurement group_id="O6" value="-0.003" spread="0.3165"/>
                    <measurement group_id="O7" value="0.070" spread="0.4603"/>
                    <measurement group_id="O8" value="0.169" spread="0.5319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes: change at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.107" spread="0.4302"/>
                    <measurement group_id="O2" value="0.229" spread="0.3998"/>
                    <measurement group_id="O3" value="0.135" spread="0.4400"/>
                    <measurement group_id="O4" value="0.012" spread="0.4596"/>
                    <measurement group_id="O5" value="0.139" spread="0.3977"/>
                    <measurement group_id="O6" value="0.039" spread="0.4169"/>
                    <measurement group_id="O7" value="0.127" spread="0.2630"/>
                    <measurement group_id="O8" value="0.176" spread="0.6274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.033" spread="0.3375"/>
                    <measurement group_id="O2" value="0.016" spread="0.3437"/>
                    <measurement group_id="O3" value="-0.079" spread="0.4826"/>
                    <measurement group_id="O4" value="0.104" spread="0.4337"/>
                    <measurement group_id="O5" value="0.068" spread="0.3168"/>
                    <measurement group_id="O6" value="-0.033" spread="0.3092"/>
                    <measurement group_id="O7" value="0.027" spread="0.2455"/>
                    <measurement group_id="O8" value="0.079" spread="0.3846"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes: change at follow-up visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="31"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.134" spread="0.3256"/>
                    <measurement group_id="O2" value="0.194" spread="0.3533"/>
                    <measurement group_id="O3" value="0.065" spread="0.6042"/>
                    <measurement group_id="O4" value="-0.022" spread="0.4419"/>
                    <measurement group_id="O5" value="0.130" spread="0.4277"/>
                    <measurement group_id="O6" value="-0.035" spread="0.4054"/>
                    <measurement group_id="O7" value="0.050" spread="0.4699"/>
                    <measurement group_id="O8" value="0.195" spread="0.4663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils: change at week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.027" spread="1.6137"/>
                    <measurement group_id="O2" value="0.205" spread="0.9185"/>
                    <measurement group_id="O3" value="-0.177" spread="1.0805"/>
                    <measurement group_id="O4" value="0.319" spread="1.0276"/>
                    <measurement group_id="O5" value="0.069" spread="1.0706"/>
                    <measurement group_id="O6" value="0.017" spread="1.1291"/>
                    <measurement group_id="O7" value="0.030" spread="1.3015"/>
                    <measurement group_id="O8" value="-0.251" spread="2.2421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.119" spread="1.5672"/>
                    <measurement group_id="O2" value="0.293" spread="1.5459"/>
                    <measurement group_id="O3" value="-0.261" spread="1.3969"/>
                    <measurement group_id="O4" value="-0.136" spread="1.0669"/>
                    <measurement group_id="O5" value="-0.109" spread="0.9653"/>
                    <measurement group_id="O6" value="-0.015" spread="1.1305"/>
                    <measurement group_id="O7" value="0.288" spread="1.7822"/>
                    <measurement group_id="O8" value="-0.190" spread="2.0749"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils: change at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.304" spread="1.6117"/>
                    <measurement group_id="O2" value="0.441" spread="1.2814"/>
                    <measurement group_id="O3" value="0.036" spread="1.1595"/>
                    <measurement group_id="O4" value="0.096" spread="1.3199"/>
                    <measurement group_id="O5" value="-0.190" spread="1.0404"/>
                    <measurement group_id="O6" value="0.338" spread="1.3577"/>
                    <measurement group_id="O7" value="-0.005" spread="0.9958"/>
                    <measurement group_id="O8" value="-0.158" spread="2.0005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.112" spread="1.6282"/>
                    <measurement group_id="O2" value="-0.001" spread="0.8996"/>
                    <measurement group_id="O3" value="-0.362" spread="1.3154"/>
                    <measurement group_id="O4" value="0.112" spread="1.2240"/>
                    <measurement group_id="O5" value="-0.250" spread="1.1720"/>
                    <measurement group_id="O6" value="-0.228" spread="0.9681"/>
                    <measurement group_id="O7" value="-0.064" spread="1.2422"/>
                    <measurement group_id="O8" value="-0.376" spread="2.1125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils: change at follow-up visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="31"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.229" spread="1.3379"/>
                    <measurement group_id="O2" value="0.261" spread="0.8874"/>
                    <measurement group_id="O3" value="-0.114" spread="1.4545"/>
                    <measurement group_id="O4" value="0.343" spread="1.3049"/>
                    <measurement group_id="O5" value="-0.020" spread="0.7731"/>
                    <measurement group_id="O6" value="-0.093" spread="1.2340"/>
                    <measurement group_id="O7" value="0.088" spread="1.4614"/>
                    <measurement group_id="O8" value="-0.562" spread="2.3227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils: change at week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.006" spread="0.0319"/>
                    <measurement group_id="O2" value="0.004" spread="0.0445"/>
                    <measurement group_id="O3" value="-0.007" spread="0.0349"/>
                    <measurement group_id="O4" value="0.010" spread="0.0258"/>
                    <measurement group_id="O5" value="0.003" spread="0.0361"/>
                    <measurement group_id="O6" value="0.001" spread="0.0191"/>
                    <measurement group_id="O7" value="0.002" spread="0.0299"/>
                    <measurement group_id="O8" value="0.002" spread="0.0343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.002" spread="0.0179"/>
                    <measurement group_id="O2" value="0.004" spread="0.0261"/>
                    <measurement group_id="O3" value="-0.009" spread="0.0276"/>
                    <measurement group_id="O4" value="0.001" spread="0.0197"/>
                    <measurement group_id="O5" value="-0.005" spread="0.0394"/>
                    <measurement group_id="O6" value="0.003" spread="0.0244"/>
                    <measurement group_id="O7" value="-0.003" spread="0.0433"/>
                    <measurement group_id="O8" value="-0.012" spread="0.0428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils: change at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.006" spread="0.0328"/>
                    <measurement group_id="O2" value="0.011" spread="0.0404"/>
                    <measurement group_id="O3" value="-0.002" spread="0.0300"/>
                    <measurement group_id="O4" value="0.001" spread="0.0256"/>
                    <measurement group_id="O5" value="-0.007" spread="0.0495"/>
                    <measurement group_id="O6" value="-0.001" spread="0.0255"/>
                    <measurement group_id="O7" value="-0.001" spread="0.0337"/>
                    <measurement group_id="O8" value="-0.004" spread="0.0323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.005" spread="0.0186"/>
                    <measurement group_id="O2" value="0.009" spread="0.0489"/>
                    <measurement group_id="O3" value="-0.012" spread="0.0313"/>
                    <measurement group_id="O4" value="0.008" spread="0.0344"/>
                    <measurement group_id="O5" value="-0.015" spread="0.0415"/>
                    <measurement group_id="O6" value="-0.004" spread="0.0188"/>
                    <measurement group_id="O7" value="-0.009" spread="0.0373"/>
                    <measurement group_id="O8" value="-0.015" spread="0.0383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils: change at follow-up visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="31"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.004" spread="0.0265"/>
                    <measurement group_id="O2" value="-0.003" spread="0.0259"/>
                    <measurement group_id="O3" value="-0.007" spread="0.0321"/>
                    <measurement group_id="O4" value="0.007" spread="0.0407"/>
                    <measurement group_id="O5" value="-0.015" spread="0.0426"/>
                    <measurement group_id="O6" value="-0.005" spread="0.0269"/>
                    <measurement group_id="O7" value="0.001" spread="0.0295"/>
                    <measurement group_id="O8" value="-0.019" spread="0.0361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils: change at week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.007" spread="0.0964"/>
                    <measurement group_id="O2" value="0.036" spread="0.0963"/>
                    <measurement group_id="O3" value="-0.004" spread="0.1092"/>
                    <measurement group_id="O4" value="-0.011" spread="0.0930"/>
                    <measurement group_id="O5" value="-0.014" spread="0.1216"/>
                    <measurement group_id="O6" value="-0.008" spread="0.1148"/>
                    <measurement group_id="O7" value="0.068" spread="0.0959"/>
                    <measurement group_id="O8" value="-0.006" spread="0.1165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.019" spread="0.1087"/>
                    <measurement group_id="O2" value="-0.000" spread="0.0734"/>
                    <measurement group_id="O3" value="-0.023" spread="0.0809"/>
                    <measurement group_id="O4" value="0.009" spread="0.0980"/>
                    <measurement group_id="O5" value="-0.029" spread="0.0915"/>
                    <measurement group_id="O6" value="-0.006" spread="0.0621"/>
                    <measurement group_id="O7" value="0.022" spread="0.0762"/>
                    <measurement group_id="O8" value="0.005" spread="0.1256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils: change at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.032" spread="0.1813"/>
                    <measurement group_id="O2" value="0.018" spread="0.1120"/>
                    <measurement group_id="O3" value="0.008" spread="0.1325"/>
                    <measurement group_id="O4" value="-0.019" spread="0.1102"/>
                    <measurement group_id="O5" value="-0.032" spread="0.1040"/>
                    <measurement group_id="O6" value="-0.012" spread="0.0832"/>
                    <measurement group_id="O7" value="0.042" spread="0.1076"/>
                    <measurement group_id="O8" value="-0.012" spread="0.1499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002" spread="0.0935"/>
                    <measurement group_id="O2" value="0.029" spread="0.1090"/>
                    <measurement group_id="O3" value="-0.025" spread="0.1351"/>
                    <measurement group_id="O4" value="0.018" spread="0.1387"/>
                    <measurement group_id="O5" value="-0.027" spread="0.1125"/>
                    <measurement group_id="O6" value="-0.007" spread="0.1025"/>
                    <measurement group_id="O7" value="-0.001" spread="0.0812"/>
                    <measurement group_id="O8" value="-0.022" spread="0.1415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils: change at follow-up visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="31"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.022" spread="0.1461"/>
                    <measurement group_id="O2" value="0.006" spread="0.0931"/>
                    <measurement group_id="O3" value="-0.023" spread="0.1196"/>
                    <measurement group_id="O4" value="-0.004" spread="0.1810"/>
                    <measurement group_id="O5" value="0.008" spread="0.1270"/>
                    <measurement group_id="O6" value="-0.008" spread="0.2483"/>
                    <measurement group_id="O7" value="0.048" spread="0.1520"/>
                    <measurement group_id="O8" value="-0.011" spread="0.1945"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes: change at week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.006" spread="0.1796"/>
                    <measurement group_id="O2" value="0.030" spread="0.0855"/>
                    <measurement group_id="O3" value="0.030" spread="0.0987"/>
                    <measurement group_id="O4" value="0.009" spread="0.0879"/>
                    <measurement group_id="O5" value="0.019" spread="0.1055"/>
                    <measurement group_id="O6" value="0.006" spread="0.0877"/>
                    <measurement group_id="O7" value="0.051" spread="0.1244"/>
                    <measurement group_id="O8" value="0.011" spread="0.1195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="34"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="30"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.006" spread="0.1509"/>
                    <measurement group_id="O2" value="0.016" spread="0.1343"/>
                    <measurement group_id="O3" value="-0.003" spread="0.0724"/>
                    <measurement group_id="O4" value="-0.014" spread="0.1055"/>
                    <measurement group_id="O5" value="0.017" spread="0.0865"/>
                    <measurement group_id="O6" value="0.013" spread="0.0983"/>
                    <measurement group_id="O7" value="0.049" spread="0.1471"/>
                    <measurement group_id="O8" value="0.025" spread="0.1496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes: change at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="25"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.035" spread="0.1904"/>
                    <measurement group_id="O2" value="0.030" spread="0.1212"/>
                    <measurement group_id="O3" value="0.013" spread="0.1234"/>
                    <measurement group_id="O4" value="-0.003" spread="0.1092"/>
                    <measurement group_id="O5" value="0.009" spread="0.0986"/>
                    <measurement group_id="O6" value="0.035" spread="0.0978"/>
                    <measurement group_id="O7" value="0.007" spread="0.1008"/>
                    <measurement group_id="O8" value="0.038" spread="0.1331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.017" spread="0.1777"/>
                    <measurement group_id="O2" value="0.017" spread="0.1069"/>
                    <measurement group_id="O3" value="-0.025" spread="0.1191"/>
                    <measurement group_id="O4" value="-0.005" spread="0.1021"/>
                    <measurement group_id="O5" value="-0.019" spread="0.0726"/>
                    <measurement group_id="O6" value="0.004" spread="0.0847"/>
                    <measurement group_id="O7" value="0.003" spread="0.1097"/>
                    <measurement group_id="O8" value="-0.012" spread="0.1200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes: change at follow-up visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="31"/>
                    <count group_id="O7" value="32"/>
                    <count group_id="O8" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.011" spread="0.1806"/>
                    <measurement group_id="O2" value="0.021" spread="0.0824"/>
                    <measurement group_id="O3" value="0.030" spread="0.1467"/>
                    <measurement group_id="O4" value="0.005" spread="0.0887"/>
                    <measurement group_id="O5" value="0.021" spread="0.0739"/>
                    <measurement group_id="O6" value="0.018" spread="0.1047"/>
                    <measurement group_id="O7" value="0.029" spread="0.1788"/>
                    <measurement group_id="O8" value="-0.006" spread="0.1282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Lipids Profile Values at Week 6</title>
        <description>Lipid parameters that were assessed: high density lipoprotein (HDL) cholesterol, triglycerides, cholesterol, low density lipoprotein (LDL) cholesterol.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure and &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream Once Daily (QD)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 0.1% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 0.3% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 1.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 3.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Cream Twice Daily (BID)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 0.3% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841 1.0% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Lipids Profile Values at Week 6</title>
          <description>Lipid parameters that were assessed: high density lipoprotein (HDL) cholesterol, triglycerides, cholesterol, low density lipoprotein (LDL) cholesterol.</description>
          <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure and &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
          <units>Microgram per deciliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HDL cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="6.65"/>
                    <measurement group_id="O2" value="0.1" spread="5.34"/>
                    <measurement group_id="O3" value="-1.3" spread="7.74"/>
                    <measurement group_id="O4" value="2.7" spread="8.33"/>
                    <measurement group_id="O5" value="1.9" spread="11.18"/>
                    <measurement group_id="O6" value="0.0" spread="6.76"/>
                    <measurement group_id="O7" value="1.2" spread="4.12"/>
                    <measurement group_id="O8" value="0.3" spread="8.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="38.84"/>
                    <measurement group_id="O2" value="-4.2" spread="59.30"/>
                    <measurement group_id="O3" value="-6.5" spread="37.30"/>
                    <measurement group_id="O4" value="1.8" spread="60.74"/>
                    <measurement group_id="O5" value="-18.9" spread="56.78"/>
                    <measurement group_id="O6" value="-8.1" spread="50.41"/>
                    <measurement group_id="O7" value="-7.0" spread="58.36"/>
                    <measurement group_id="O8" value="-4.4" spread="55.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="16.39"/>
                    <measurement group_id="O2" value="-5.6" spread="27.59"/>
                    <measurement group_id="O3" value="-12.8" spread="20.53"/>
                    <measurement group_id="O4" value="6.8" spread="24.09"/>
                    <measurement group_id="O5" value="-10.4" spread="30.79"/>
                    <measurement group_id="O6" value="-0.2" spread="18.70"/>
                    <measurement group_id="O7" value="5.3" spread="30.58"/>
                    <measurement group_id="O8" value="-0.9" spread="19.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="30"/>
                    <count group_id="O8" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="14.45"/>
                    <measurement group_id="O2" value="-6.3" spread="25.28"/>
                    <measurement group_id="O3" value="-12.1" spread="16.44"/>
                    <measurement group_id="O4" value="2.1" spread="20.13"/>
                    <measurement group_id="O5" value="-11.0" spread="29.06"/>
                    <measurement group_id="O6" value="-0.8" spread="14.48"/>
                    <measurement group_id="O7" value="4.4" spread="23.55"/>
                    <measurement group_id="O8" value="-1.1" spread="16.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Ratio of LDL Cholesterol to HDL Cholesterol Lipids Profile at Week 6</title>
        <description>Mean change in total cholesterol/HDL cholesterol ratio was assessed and reported.</description>
        <time_frame>Baseline, Week 6</time_frame>
        <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream Once Daily (QD)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 0.1% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 0.3% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 1.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 3.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Cream Twice Daily (BID)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 0.3% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841 1.0% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Ratio of LDL Cholesterol to HDL Cholesterol Lipids Profile at Week 6</title>
          <description>Mean change in total cholesterol/HDL cholesterol ratio was assessed and reported.</description>
          <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure.</population>
          <units>Ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="30"/>
                <count group_id="O8" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.31"/>
                    <measurement group_id="O2" value="-0.1" spread="0.48"/>
                    <measurement group_id="O3" value="-0.2" spread="0.40"/>
                    <measurement group_id="O4" value="-0.0" spread="0.32"/>
                    <measurement group_id="O5" value="-0.3" spread="0.77"/>
                    <measurement group_id="O6" value="-0.0" spread="0.35"/>
                    <measurement group_id="O7" value="0.0" spread="0.46"/>
                    <measurement group_id="O8" value="-0.0" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Electrocardiogram (ECG) Parameter- Heart Rate at Weeks 2 and 6</title>
        <time_frame>Baseline, Weeks 2 and 6</time_frame>
        <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream Once Daily (QD)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 0.1% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 0.3% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 1.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 3.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Cream Twice Daily (BID)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 0.3% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841 1.0% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Electrocardiogram (ECG) Parameter- Heart Rate at Weeks 2 and 6</title>
          <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="36"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="36"/>
                    <count group_id="O7" value="36"/>
                    <count group_id="O8" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.8" spread="11.45"/>
                    <measurement group_id="O2" value="66.9" spread="9.33"/>
                    <measurement group_id="O3" value="68.4" spread="14.66"/>
                    <measurement group_id="O4" value="64.9" spread="9.05"/>
                    <measurement group_id="O5" value="64.9" spread="12.26"/>
                    <measurement group_id="O6" value="66.9" spread="12.03"/>
                    <measurement group_id="O7" value="68.2" spread="12.11"/>
                    <measurement group_id="O8" value="68.1" spread="12.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="26"/>
                    <count group_id="O7" value="34"/>
                    <count group_id="O8" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="10.05"/>
                    <measurement group_id="O2" value="-0.5" spread="8.03"/>
                    <measurement group_id="O3" value="-1.8" spread="11.53"/>
                    <measurement group_id="O4" value="-0.6" spread="7.88"/>
                    <measurement group_id="O5" value="1.9" spread="8.01"/>
                    <measurement group_id="O6" value="2.2" spread="8.76"/>
                    <measurement group_id="O7" value="1.7" spread="9.13"/>
                    <measurement group_id="O8" value="1.7" spread="12.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="6.19"/>
                    <measurement group_id="O2" value="-1.1" spread="7.65"/>
                    <measurement group_id="O3" value="-1.7" spread="9.06"/>
                    <measurement group_id="O4" value="0.8" spread="8.53"/>
                    <measurement group_id="O5" value="-0.3" spread="8.46"/>
                    <measurement group_id="O6" value="-0.8" spread="8.23"/>
                    <measurement group_id="O7" value="0.5" spread="8.76"/>
                    <measurement group_id="O8" value="-0.4" spread="12.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PR, QRS, QTCF and QT Interval at Weeks 2 and 6</title>
        <time_frame>Baseline, Weeks 2 and 6</time_frame>
        <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream Once Daily (QD)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 0.1% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 0.3% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 1.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 3.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Cream Twice Daily (BID)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 0.3% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841 1.0% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PR, QRS, QTCF and QT Interval at Weeks 2 and 6</title>
          <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
          <units>Milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="36"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR interval: baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="36"/>
                    <count group_id="O7" value="36"/>
                    <count group_id="O8" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.9" spread="23.30"/>
                    <measurement group_id="O2" value="160.2" spread="24.01"/>
                    <measurement group_id="O3" value="161.4" spread="27.59"/>
                    <measurement group_id="O4" value="162.5" spread="22.04"/>
                    <measurement group_id="O5" value="160.7" spread="24.20"/>
                    <measurement group_id="O6" value="156.4" spread="22.65"/>
                    <measurement group_id="O7" value="157.9" spread="23.55"/>
                    <measurement group_id="O8" value="157.8" spread="23.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="26"/>
                    <count group_id="O7" value="34"/>
                    <count group_id="O8" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="14.41"/>
                    <measurement group_id="O2" value="-0.9" spread="15.92"/>
                    <measurement group_id="O3" value="0.7" spread="18.54"/>
                    <measurement group_id="O4" value="0.3" spread="10.13"/>
                    <measurement group_id="O5" value="1.1" spread="14.42"/>
                    <measurement group_id="O6" value="6.0" spread="14.79"/>
                    <measurement group_id="O7" value="1.2" spread="16.06"/>
                    <measurement group_id="O8" value="2.1" spread="7.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR interval: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="10.16"/>
                    <measurement group_id="O2" value="-0.1" spread="13.81"/>
                    <measurement group_id="O3" value="2.8" spread="19.66"/>
                    <measurement group_id="O4" value="2.9" spread="13.63"/>
                    <measurement group_id="O5" value="3.5" spread="21.88"/>
                    <measurement group_id="O6" value="4.0" spread="14.56"/>
                    <measurement group_id="O7" value="6.5" spread="19.15"/>
                    <measurement group_id="O8" value="5.7" spread="16.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval: baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="36"/>
                    <count group_id="O7" value="36"/>
                    <count group_id="O8" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5" spread="9.36"/>
                    <measurement group_id="O2" value="91.5" spread="9.71"/>
                    <measurement group_id="O3" value="91.1" spread="9.29"/>
                    <measurement group_id="O4" value="93.0" spread="11.13"/>
                    <measurement group_id="O5" value="93.1" spread="8.69"/>
                    <measurement group_id="O6" value="92.2" spread="13.00"/>
                    <measurement group_id="O7" value="92.4" spread="13.30"/>
                    <measurement group_id="O8" value="91.5" spread="11.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="26"/>
                    <count group_id="O7" value="34"/>
                    <count group_id="O8" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="8.02"/>
                    <measurement group_id="O2" value="-0.4" spread="5.34"/>
                    <measurement group_id="O3" value="-1.3" spread="3.46"/>
                    <measurement group_id="O4" value="-0.8" spread="5.64"/>
                    <measurement group_id="O5" value="0.1" spread="4.79"/>
                    <measurement group_id="O6" value="1.5" spread="9.29"/>
                    <measurement group_id="O7" value="0.2" spread="8.07"/>
                    <measurement group_id="O8" value="1.0" spread="5.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS interval: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="6.55"/>
                    <measurement group_id="O2" value="1.4" spread="5.62"/>
                    <measurement group_id="O3" value="-0.5" spread="4.76"/>
                    <measurement group_id="O4" value="-0.9" spread="4.04"/>
                    <measurement group_id="O5" value="-1.3" spread="4.00"/>
                    <measurement group_id="O6" value="0.9" spread="6.37"/>
                    <measurement group_id="O7" value="0.6" spread="5.49"/>
                    <measurement group_id="O8" value="0.7" spread="5.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTCF interval: baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="36"/>
                    <count group_id="O7" value="36"/>
                    <count group_id="O8" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="407.7" spread="17.78"/>
                    <measurement group_id="O2" value="397.9" spread="15.98"/>
                    <measurement group_id="O3" value="403.8" spread="22.43"/>
                    <measurement group_id="O4" value="408.5" spread="18.42"/>
                    <measurement group_id="O5" value="401.0" spread="16.29"/>
                    <measurement group_id="O6" value="403.0" spread="16.65"/>
                    <measurement group_id="O7" value="397.7" spread="17.05"/>
                    <measurement group_id="O8" value="405.0" spread="20.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTCF interval: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="26"/>
                    <count group_id="O7" value="34"/>
                    <count group_id="O8" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.7" spread="11.86"/>
                    <measurement group_id="O2" value="-1.5" spread="13.70"/>
                    <measurement group_id="O3" value="-3.9" spread="15.60"/>
                    <measurement group_id="O4" value="2.6" spread="16.20"/>
                    <measurement group_id="O5" value="-0.6" spread="12.75"/>
                    <measurement group_id="O6" value="1.4" spread="15.56"/>
                    <measurement group_id="O7" value="2.4" spread="10.32"/>
                    <measurement group_id="O8" value="-4.6" spread="15.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTCF interval: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" spread="14.61"/>
                    <measurement group_id="O2" value="-0.5" spread="14.93"/>
                    <measurement group_id="O3" value="-1.9" spread="14.37"/>
                    <measurement group_id="O4" value="0.3" spread="17.19"/>
                    <measurement group_id="O5" value="-1.4" spread="14.93"/>
                    <measurement group_id="O6" value="4.6" spread="14.27"/>
                    <measurement group_id="O7" value="2.0" spread="11.94"/>
                    <measurement group_id="O8" value="-0.2" spread="9.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval: baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="36"/>
                    <count group_id="O7" value="36"/>
                    <count group_id="O8" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395.2" spread="31.53"/>
                    <measurement group_id="O2" value="385.3" spread="23.64"/>
                    <measurement group_id="O3" value="388.8" spread="33.66"/>
                    <measurement group_id="O4" value="401.0" spread="25.23"/>
                    <measurement group_id="O5" value="392.0" spread="27.36"/>
                    <measurement group_id="O6" value="390.9" spread="24.87"/>
                    <measurement group_id="O7" value="383.8" spread="30.79"/>
                    <measurement group_id="O8" value="390.6" spread="32.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="26"/>
                    <count group_id="O7" value="34"/>
                    <count group_id="O8" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="23.16"/>
                    <measurement group_id="O2" value="-1.3" spread="17.73"/>
                    <measurement group_id="O3" value="-1.1" spread="19.31"/>
                    <measurement group_id="O4" value="3.5" spread="21.06"/>
                    <measurement group_id="O5" value="-4.5" spread="15.75"/>
                    <measurement group_id="O6" value="1.2" spread="24.03"/>
                    <measurement group_id="O7" value="-2.3" spread="18.69"/>
                    <measurement group_id="O8" value="-4.6" spread="25.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT interval: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="19.54"/>
                    <measurement group_id="O2" value="1.3" spread="18.11"/>
                    <measurement group_id="O3" value="0.9" spread="16.11"/>
                    <measurement group_id="O4" value="-4.1" spread="23.42"/>
                    <measurement group_id="O5" value="-0.9" spread="20.12"/>
                    <measurement group_id="O6" value="7.8" spread="24.11"/>
                    <measurement group_id="O7" value="-1.4" spread="20.47"/>
                    <measurement group_id="O8" value="4.0" spread="27.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vital Signs- Blood Pressure (BP) at Weeks 2 and 6</title>
        <description>Blood pressure included supine and sitting systolic and diastolic BP.</description>
        <time_frame>Baseline, Weeks 2 and 6</time_frame>
        <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure and &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream Once Daily (QD)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 0.1% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 0.3% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 1.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 3.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Cream Twice Daily (BID)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 0.3% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841 1.0% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Signs- Blood Pressure (BP) at Weeks 2 and 6</title>
          <description>Blood pressure included supine and sitting systolic and diastolic BP.</description>
          <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;Overall Number of Participants Analyzed&quot; signifies participants evaluable for this outcome measure and &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
          <units>Millimeters of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="29"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Supine systolic BP: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="26"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.3" spread="12.01"/>
                    <measurement group_id="O2" value="123.2" spread="12.35"/>
                    <measurement group_id="O3" value="123.0" spread="13.89"/>
                    <measurement group_id="O4" value="119.7" spread="9.08"/>
                    <measurement group_id="O5" value="122.6" spread="12.76"/>
                    <measurement group_id="O6" value="123.1" spread="12.40"/>
                    <measurement group_id="O7" value="117.1" spread="14.07"/>
                    <measurement group_id="O8" value="118.9" spread="12.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine systolic BP: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="20"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="21"/>
                    <count group_id="O8" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="11.55"/>
                    <measurement group_id="O2" value="-1.4" spread="9.61"/>
                    <measurement group_id="O3" value="0.5" spread="14.73"/>
                    <measurement group_id="O4" value="2.3" spread="6.99"/>
                    <measurement group_id="O5" value="-0.3" spread="10.25"/>
                    <measurement group_id="O6" value="-0.3" spread="8.02"/>
                    <measurement group_id="O7" value="3.5" spread="13.65"/>
                    <measurement group_id="O8" value="2.9" spread="8.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine systolic BP: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="19"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="21"/>
                    <count group_id="O8" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="12.98"/>
                    <measurement group_id="O2" value="1.1" spread="10.06"/>
                    <measurement group_id="O3" value="2.0" spread="14.05"/>
                    <measurement group_id="O4" value="0.2" spread="9.13"/>
                    <measurement group_id="O5" value="-3.4" spread="11.02"/>
                    <measurement group_id="O6" value="-1.4" spread="10.49"/>
                    <measurement group_id="O7" value="2.1" spread="12.41"/>
                    <measurement group_id="O8" value="0.6" spread="10.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting systolic BP: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="19"/>
                    <count group_id="O6" value="16"/>
                    <count group_id="O7" value="18"/>
                    <count group_id="O8" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.7" spread="13.05"/>
                    <measurement group_id="O2" value="120.8" spread="10.26"/>
                    <measurement group_id="O3" value="120.2" spread="12.43"/>
                    <measurement group_id="O4" value="116.9" spread="17.76"/>
                    <measurement group_id="O5" value="124.6" spread="11.25"/>
                    <measurement group_id="O6" value="119.4" spread="12.96"/>
                    <measurement group_id="O7" value="122.9" spread="15.25"/>
                    <measurement group_id="O8" value="125.6" spread="12.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting systolic BP: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="12.12"/>
                    <measurement group_id="O2" value="-1.9" spread="11.86"/>
                    <measurement group_id="O3" value="-3.9" spread="14.54"/>
                    <measurement group_id="O4" value="1.3" spread="13.59"/>
                    <measurement group_id="O5" value="-2.4" spread="11.76"/>
                    <measurement group_id="O6" value="-3.1" spread="10.46"/>
                    <measurement group_id="O7" value="1.1" spread="9.81"/>
                    <measurement group_id="O8" value="4.4" spread="11.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting systolic BP: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="12.24"/>
                    <measurement group_id="O2" value="-7.5" spread="8.67"/>
                    <measurement group_id="O3" value="-9.4" spread="8.95"/>
                    <measurement group_id="O4" value="1.0" spread="14.63"/>
                    <measurement group_id="O5" value="-8.4" spread="10.81"/>
                    <measurement group_id="O6" value="-0.6" spread="14.40"/>
                    <measurement group_id="O7" value="-3.6" spread="8.37"/>
                    <measurement group_id="O8" value="-1.5" spread="5.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine diastolic BP: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="26"/>
                    <count group_id="O7" value="23"/>
                    <count group_id="O8" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.7" spread="9.28"/>
                    <measurement group_id="O2" value="75.2" spread="8.79"/>
                    <measurement group_id="O3" value="78.8" spread="8.39"/>
                    <measurement group_id="O4" value="74.5" spread="8.26"/>
                    <measurement group_id="O5" value="75.9" spread="8.78"/>
                    <measurement group_id="O6" value="77.5" spread="8.71"/>
                    <measurement group_id="O7" value="74.4" spread="8.20"/>
                    <measurement group_id="O8" value="73.7" spread="8.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine diastolic BP: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="20"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="21"/>
                    <count group_id="O8" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="7.51"/>
                    <measurement group_id="O2" value="0.6" spread="6.47"/>
                    <measurement group_id="O3" value="-0.4" spread="8.50"/>
                    <measurement group_id="O4" value="1.6" spread="10.33"/>
                    <measurement group_id="O5" value="1.2" spread="8.32"/>
                    <measurement group_id="O6" value="-2.8" spread="6.69"/>
                    <measurement group_id="O7" value="1.6" spread="8.89"/>
                    <measurement group_id="O8" value="1.4" spread="7.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine diastolic BP: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="19"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="21"/>
                    <count group_id="O8" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="7.69"/>
                    <measurement group_id="O2" value="1.5" spread="7.61"/>
                    <measurement group_id="O3" value="-0.7" spread="8.32"/>
                    <measurement group_id="O4" value="0.5" spread="7.96"/>
                    <measurement group_id="O5" value="-0.9" spread="10.65"/>
                    <measurement group_id="O6" value="-1.6" spread="6.22"/>
                    <measurement group_id="O7" value="1.9" spread="9.72"/>
                    <measurement group_id="O8" value="0.5" spread="6.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting diastolic BP: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="19"/>
                    <count group_id="O6" value="16"/>
                    <count group_id="O7" value="18"/>
                    <count group_id="O8" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5" spread="9.28"/>
                    <measurement group_id="O2" value="80.1" spread="6.76"/>
                    <measurement group_id="O3" value="77.8" spread="10.02"/>
                    <measurement group_id="O4" value="69.6" spread="11.48"/>
                    <measurement group_id="O5" value="80.9" spread="8.21"/>
                    <measurement group_id="O6" value="75.1" spread="5.77"/>
                    <measurement group_id="O7" value="77.1" spread="12.00"/>
                    <measurement group_id="O8" value="80.3" spread="7.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting diastolic BP: change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="7"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="8.49"/>
                    <measurement group_id="O2" value="0.7" spread="7.93"/>
                    <measurement group_id="O3" value="0.0" spread="9.44"/>
                    <measurement group_id="O4" value="1.6" spread="12.00"/>
                    <measurement group_id="O5" value="-2.9" spread="10.77"/>
                    <measurement group_id="O6" value="1.7" spread="8.20"/>
                    <measurement group_id="O7" value="4.5" spread="5.80"/>
                    <measurement group_id="O8" value="-1.2" spread="6.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting diastolic BP: change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="9.90"/>
                    <measurement group_id="O2" value="0.0" spread="5.79"/>
                    <measurement group_id="O3" value="-1.6" spread="11.97"/>
                    <measurement group_id="O4" value="1.1" spread="15.61"/>
                    <measurement group_id="O5" value="-5.3" spread="9.27"/>
                    <measurement group_id="O6" value="-2.8" spread="12.60"/>
                    <measurement group_id="O7" value="-0.3" spread="7.89"/>
                    <measurement group_id="O8" value="0.4" spread="8.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vital Signs- Pulse Rate at Weeks 2 and 6</title>
        <time_frame>Baseline, Weeks 2 and 6</time_frame>
        <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream Once Daily (QD)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 0.1% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 0.3% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 1.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 3.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Cream Twice Daily (BID)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 0.3% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841 1.0% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Signs- Pulse Rate at Weeks 2 and 6</title>
          <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="36"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="36"/>
                    <count group_id="O7" value="36"/>
                    <count group_id="O8" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6" spread="12.58"/>
                    <measurement group_id="O2" value="69.5" spread="9.82"/>
                    <measurement group_id="O3" value="72.9" spread="14.30"/>
                    <measurement group_id="O4" value="67.9" spread="9.31"/>
                    <measurement group_id="O5" value="68.8" spread="11.76"/>
                    <measurement group_id="O6" value="69.4" spread="11.15"/>
                    <measurement group_id="O7" value="70.1" spread="11.18"/>
                    <measurement group_id="O8" value="68.2" spread="9.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="26"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="10.41"/>
                    <measurement group_id="O2" value="0.2" spread="8.11"/>
                    <measurement group_id="O3" value="-2.5" spread="9.66"/>
                    <measurement group_id="O4" value="1.1" spread="9.13"/>
                    <measurement group_id="O5" value="0.5" spread="6.54"/>
                    <measurement group_id="O6" value="3.7" spread="9.47"/>
                    <measurement group_id="O7" value="2.8" spread="8.28"/>
                    <measurement group_id="O8" value="4.1" spread="9.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="10.59"/>
                    <measurement group_id="O2" value="0.3" spread="8.04"/>
                    <measurement group_id="O3" value="-1.4" spread="11.90"/>
                    <measurement group_id="O4" value="0.9" spread="9.71"/>
                    <measurement group_id="O5" value="1.8" spread="8.73"/>
                    <measurement group_id="O6" value="4.1" spread="6.76"/>
                    <measurement group_id="O7" value="0.5" spread="9.12"/>
                    <measurement group_id="O8" value="1.8" spread="8.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vital Signs- Temperature at Weeks 2 and 6</title>
        <time_frame>Baseline, Weeks 2 and 6</time_frame>
        <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream Once Daily (QD)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 0.1% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 0.3% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 1.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 3.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Cream Twice Daily (BID)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 0.3% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841 1.0% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Signs- Temperature at Weeks 2 and 6</title>
          <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug. Here, &quot;number analyzed&quot; signifies participants evaluable for the each specified time point.</population>
          <units>Degree Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="36"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="37"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="36"/>
                    <count group_id="O7" value="36"/>
                    <count group_id="O8" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" spread="0.33"/>
                    <measurement group_id="O2" value="36.5" spread="0.43"/>
                    <measurement group_id="O3" value="36.6" spread="0.44"/>
                    <measurement group_id="O4" value="36.6" spread="0.33"/>
                    <measurement group_id="O5" value="36.5" spread="0.37"/>
                    <measurement group_id="O6" value="36.5" spread="0.29"/>
                    <measurement group_id="O7" value="36.6" spread="0.41"/>
                    <measurement group_id="O8" value="36.6" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="26"/>
                    <count group_id="O7" value="33"/>
                    <count group_id="O8" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.41"/>
                    <measurement group_id="O2" value="-0.1" spread="0.30"/>
                    <measurement group_id="O3" value="0.0" spread="0.38"/>
                    <measurement group_id="O4" value="-0.0" spread="0.43"/>
                    <measurement group_id="O5" value="0.1" spread="0.35"/>
                    <measurement group_id="O6" value="-0.0" spread="0.38"/>
                    <measurement group_id="O7" value="0.0" spread="0.34"/>
                    <measurement group_id="O8" value="0.0" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="32"/>
                    <count group_id="O5" value="30"/>
                    <count group_id="O6" value="24"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" spread="0.40"/>
                    <measurement group_id="O2" value="-0.0" spread="0.29"/>
                    <measurement group_id="O3" value="0.0" spread="0.38"/>
                    <measurement group_id="O4" value="0.1" spread="0.32"/>
                    <measurement group_id="O5" value="0.0" spread="0.29"/>
                    <measurement group_id="O6" value="0.1" spread="0.50"/>
                    <measurement group_id="O7" value="0.0" spread="0.37"/>
                    <measurement group_id="O8" value="-0.0" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Each Severity Grade in Local Tolerability Assessments</title>
        <description>Local tolerability skin assessments were performed by the investigator and graded based on severity from grade 0 to 4 as: grade 0=none (no evidence of local intolerance); grade 1=mild (minimal erythema and/or oedema, slight glazed appearance); grade 2= moderate (definite erythema and/or oedema with peeling and/or cracking but needs no adaptation of posology) grade 3=severe (erythema, oedema glazing with fissures, few vesicles or papules consider removing topical agent [if still in place]) and grade 4= very severe (strong reaction spreading beyond the treated area, bullous reaction, erosions: removal of topical agent [if still in place]). Higher grades indicated worsening of condition. Only those categories in which at least 1 participant had data were reported.</description>
        <time_frame>Day 1 and any day on of Week 1, 2, 4, 6: pre dose (before application of IP) and post dose (after application of IP); Follow up visit (28 days after last dose of study drug = maximum up to Day 71) and Early termination (anytime within week 11)</time_frame>
        <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Cream Once Daily (QD)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O2">
            <title>PF-06700841 0.1% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O3">
            <title>PF-06700841 0.3% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O4">
            <title>PF-06700841 1.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O5">
            <title>PF-06700841 3.0% Cream QD</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O6">
            <title>Vehicle Cream Twice Daily (BID)</title>
            <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O7">
            <title>PF-06700841 0.3% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
          <group group_id="O8">
            <title>PF-06700841 1.0% Cream BID</title>
            <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Each Severity Grade in Local Tolerability Assessments</title>
          <description>Local tolerability skin assessments were performed by the investigator and graded based on severity from grade 0 to 4 as: grade 0=none (no evidence of local intolerance); grade 1=mild (minimal erythema and/or oedema, slight glazed appearance); grade 2= moderate (definite erythema and/or oedema with peeling and/or cracking but needs no adaptation of posology) grade 3=severe (erythema, oedema glazing with fissures, few vesicles or papules consider removing topical agent [if still in place]) and grade 4= very severe (strong reaction spreading beyond the treated area, bullous reaction, erosions: removal of topical agent [if still in place]). Higher grades indicated worsening of condition. Only those categories in which at least 1 participant had data were reported.</description>
          <population>Safety analysis set included all participants who were randomly assigned to study drug and who applied at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="36"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1: tolerability before: none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="36"/>
                    <measurement group_id="O6" value="35"/>
                    <measurement group_id="O7" value="34"/>
                    <measurement group_id="O8" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: tolerability before: mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: tolerability before: moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: tolerability after: none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="34"/>
                    <measurement group_id="O7" value="32"/>
                    <measurement group_id="O8" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: tolerability after: mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1: tolerability after: moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1: tolerability before: none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="30"/>
                    <measurement group_id="O6" value="30"/>
                    <measurement group_id="O7" value="33"/>
                    <measurement group_id="O8" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1: tolerability before: mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1: tolerability before: moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1: tolerability after: none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="27"/>
                    <measurement group_id="O7" value="32"/>
                    <measurement group_id="O8" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1: tolerability after: mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1: tolerability after: moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: tolerability before: none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="30"/>
                    <measurement group_id="O6" value="23"/>
                    <measurement group_id="O7" value="31"/>
                    <measurement group_id="O8" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: tolerability before: mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: tolerability before: moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: tolerability after: none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="23"/>
                    <measurement group_id="O7" value="32"/>
                    <measurement group_id="O8" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: tolerability after: mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: tolerability after: moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: tolerability before: none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="30"/>
                    <measurement group_id="O6" value="24"/>
                    <measurement group_id="O7" value="31"/>
                    <measurement group_id="O8" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: tolerability before: mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: tolerability before: moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: tolerability after: none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="24"/>
                    <measurement group_id="O7" value="31"/>
                    <measurement group_id="O8" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: tolerability after: mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: tolerability after: moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6: tolerability before: none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="30"/>
                    <measurement group_id="O6" value="21"/>
                    <measurement group_id="O7" value="30"/>
                    <measurement group_id="O8" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6: tolerability before: mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6: tolerability before: moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6: tolerability after: none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="22"/>
                    <measurement group_id="O7" value="30"/>
                    <measurement group_id="O8" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6: tolerability after: mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6: tolerability after: moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Early termination:tolerability: none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Early termination:tolerability: mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Early termination:tolerability: moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Early termination:tolerability: severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow Up: tolerability: none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="25"/>
                    <measurement group_id="O7" value="26"/>
                    <measurement group_id="O8" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow Up: tolerability: mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow Up: tolerability: moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow Up: tolerability: severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline (Day 1) up to at least 28 days after last dose of study drug (approximately up to Week 11)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vehicle Cream Once Daily (QD)</title>
          <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
        </group>
        <group group_id="E2">
          <title>PF-06700841 0.1% Cream QD</title>
          <description>Participants or caregivers of participants, topically applied PF-06700841 0.1 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
        </group>
        <group group_id="E3">
          <title>PF-06700841 0.3% Cream QD</title>
          <description>Participants or caregivers of participants, topically applied PF-06700841 0.3 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
        </group>
        <group group_id="E4">
          <title>PF-06700841 1.0% Cream QD</title>
          <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
        </group>
        <group group_id="E5">
          <title>PF-06700841 3.0% Cream QD</title>
          <description>Participants or caregivers of participants, topically applied PF-06700841 3.0 % cream on all eligible AD areas (of participants) once daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
        </group>
        <group group_id="E6">
          <title>Vehicle Cream Twice Daily (BID)</title>
          <description>Participants or caregivers of participants, topically applied vehicle cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
        </group>
        <group group_id="E7">
          <title>PF-06700841 0.3% Cream BID</title>
          <description>Participants or caregivers of participants, topically applied PF-06700841 0.3% cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
        </group>
        <group group_id="E8">
          <title>PF-06700841 1.0% Cream BID</title>
          <description>Participants or caregivers of participants, topically applied PF-06700841 1.0 % cream on all eligible AD areas (of participants) twice daily for a maximum of 6 weeks. Eligibility of AD areas to be treated were determined on Day 1 by investigator. Participants were followed up for 4 weeks after last dose.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA v23.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Swelling of eyelid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Administration site warmth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Application site acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Cockroach allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Mite allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Allergy to animal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Eczema infected</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Kaposi's varicelliform eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Viral rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave inversion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Lipids abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pregnancy test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Increased viscosity of bronchial secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Granuloma annulare</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Solar urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

